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Summary 
Summary 
Background 
The neglected tropical disease (NTD), lymphatic filariasis (LF), is endemic in 73 countries, primarily 
among impoverished populations [1]. LF is caused by infection with the filarial nematodes 
Wuchereria bancrofti, Brugia malayi, or B. timori, which are transmitted to humans by a variety of 
mosquito genera, including Anopheles, Culex, and Aedes [2]. Infection with LF can damage the 
lymphatic system, causing permanent disability including hydrocele, lymphedema, and elephantiasis 
[3]. Though not all infections lead to disability, the health burden due to LF is considerable, 
estimated at 2.74 million disability-adjusted life years (DALYs) (1.73m-4.00m) [4]. The disfiguring 
disability associated with LF also causes stigma, social adversity, and economic hardship [5-7].  
In 1997, LF was named by the World Health Assembly (WHA) as a potentially eradicable disease [8], 
in part because it is preventable through once yearly treatment administered through mass drug 
administration (MDA) using albendazole with ivermectin or diethylcarbamazine citrate (DEC). It is 
this prevention strategy that underlies the Global Program to Eliminate Lymphatic Filariasis (GPELF), 
which aims to globally eliminate LF as a public health problem by 2020 [9]. The efforts of the GPELF 
are supported through public and private partnerships, among which include the pharmaceutical 
companies Merck & Co., GlaxoSmithKline (GSK), and Eisai, which currently donate all of the 
medications used to carry out the MDA strategy [10,11]. 
In the 15 years since the inception of the GPELF, there has been great progress made against LF. In 
2013 alone, over 410 million treatments were distributed to prevent LF transmission. Of the 73 LF-
endemic countries, 59 have carried out MDA as part of the GPELF strategy, and 15 others are now 
conducting post-MDA surveillance to determine if local elimination has been achieved. However,  12 
countries are yet to finish mapping and many countries are currently distributing treatments to 
relatively small percentages of their at-risk populations [12]. Problems with systematic non-
compliance, contraindications of the antifilarials in some areas in Central Africa, and insecure 
funding also threaten the program [13,14].  
Aims  
This project has been undertaken in order to provide decision makers with evidence-based guidance 
on the rationale for investing in LF eradication. As such, this project aims to:   
 Predict the duration of MDA necessary to reach local elimination for a variety of 
transmission archetypes using an existing model of LF transmission 
Summary 
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 Develop plausible scenarios leading to global elimination and eradication under varying 
levels of MDA scale-up 
 
 Project the number of treatments required for each scenario 
 
 Estimate the time in which local elimination will be achieved in each country in each 
scenario 
 
 Estimate the potential economic and financial investment needed to interrupt LF 
transmission and conduct surveillance activities under each of the scenarios 
 
 Quantify the potential health impact of eradicating LF in terms of DALYs averted 
 
 Estimate the cost-effectiveness of different intensities of MDA scale-up 
 
 Project the potential health systems savings as a result of averted LF-related morbidity 
 
 Monetarily value possible gains in worker productivity resulting from averted LF-related 
morbidity 
 
Methods 
In collaboration with a diverse group of stakeholders, decision-makers, and program experts, we 
developed a global elimination and three eradication scenarios. The global elimination scenario 
serves as the counter-factual case, mirroring the current geographic coverage and rate of MDA 
scale-up seen under the GPELF. In contrast, the three eradication scenarios include all LF endemic 
countries but differ in their rates of MDA scale-up. Eradication I extends MDA to all endemic 
countries under the average rate of MDA seen under the GPELF; eradication II assumes a more rapid 
scale-up, with 20% of each country’s at-risk population added to the MDA schedule annually; and 
eradication III represents the ideal scenario, assuming all at-risk populations are treated with MDA 
immediately.  
Using EpiFil [15], a deterministic model of LF transmission, we determined the number of annual 
rounds of MDA necessary to reach local elimination for a range of transmission archetypes. We then 
used the model estimates to assess the number of years of MDA and associated number of 
treatments required to interrupt LF transmission in each country in each scenario. 
In order to assess the financial costs of interrupting LF transmission in each of the scenarios, we built 
a micro-costing model from the perspective of each LF endemic country’s health system. We also 
considered the value of the donated pharmaceuticals and volunteer time in the assessment of 
economic costs. In order to account for the health impact of varying intensities of MDA scale-up, we 
simulated the amount of LF-related disability arising under each of the scenarios over a 50 year time 
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horizon. The health impact estimates were then paired with the financial cost estimates in order to 
assess the cost-effectiveness of LF eradication.  Using the WHO CHOICE database [16], we also 
determined the potential savings to health systems as a result of averted LF-related disability. 
Further, we monetarily valued the societal economic gains from LF eradication by pairing the 
potential increase in worker productivity due to averted LF-related disability with country or region 
specific daily per worker agriculture wage estimates taken from the World Bank [17]. 
Principal Findings 
If MDA scale-up is maintained at the current rate, our model suggests that LF transmission will not 
be interrupted until 2050 (global elimination and eradication I scenarios). In contrast, providing MDA 
to all at-risk populations in all countries immediately (eradication III) is projected to result in the 
interruption of LF transmission by 2028. Providing treatments to all LF endemic countries at the 
current rate of scale-up (eradication I) is estimated to require 4,667 million treatments (95% CrI: 
4,419m-4,904m). However, as population growth rates are taken into account, decreasing the time 
required to reach eradication is also projected to decrease the number of treatments required, with 
the eradication II scenario projected to require 4,369 million treatments (95% CrI: 4,133m–4,594m) 
and the eradication III scenario requiring 4,159 million treatments (95% CrI: 3,924m-4,382m). The 
financial cost of completing the current global elimination program is projected at 929.2 million US 
dollars (USD) (95% CrI: 883.5m-971.5m), while eradication I is projected to require a financial 
investment of 1,289 million USD (95% CrI: 1,227m-1,345m). Treating all populations in all endemic 
countries immediately (eradication III) will require a financial investment totaling 1,235 million USD 
(95% CrI: 1,172m-1,300m). The economic costs, which take into account the value of the donated 
pharmaceuticals and volunteer time together with the actual monetary expenditure required 
(financial costs), are projected at 5.21 billion USD (95% CrI: 4.91-5.45) under the global elimination 
scenario, 7.94 billion USD (95% CrI: 7.50bn-8.30bn USD) for eradication I, 8.00 billion USD (7.55bn-
8.37bn) for eradication II and 7.57 billion USD (7.12bn-7.94bn) for eradication III. Approximately half 
of the economic costs are due to the value of the donated drugs.  
Against the global elimination scenario, the health impact of the eradication I scenario is projected 
to result in approximately 1.72 million DALYs averted (95% CrI: 1.09m-2.61m), while the eradication 
III scenario is projected to result in 4.38 million DALYs averted (95% CrI: 2.79m-6.50m) over the same 
timeframe. The cost-effectiveness of LF eradication is also projected to be greatest when all LF at-
risk populations are treated immediately, with an incremental cost-effectiveness ratio (ICER) under 
the eradication III scenario estimated at 72.9 USD/DALY averted (95% CrI: 47.7-110). Health systems 
savings also increase with increased rates of MDA scale-up, with the most savings expected under 
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the eradication III scenario (483 million USD (95% CrI: 219m-903m). Gains in worker productivity also 
increase with increased rates of MDA scale-up, estimated at about 14 billion USD (95% CrI: 8.58bn-
22.0bn) under eradication III versus 3.41 billion USD (95% CrI: 2.03bn-5.36bn) in eradication I. 
Conclusions 
While pursuing LF eradication has many benefits, our analysis indicates reaching LF eradication in 
the shortest amount of time possible is preferred across a number of indicators. The results of our 
analyses indicate that eradicating LF could be among the best buy strategies in public health, though 
the success of eradicating LF will depend on the political engagement and enthusiasm at all levels.    
1. Introduction 
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1 Introduction 
1.1. Neglected Tropical Diseases 
Neglected tropical diseases (NTDs) are a group of helminthic, bacterial, viral, fungal and protozoan 
infections that cause significant morbidity [18]. NTDs persist in areas where vector control, access to 
clean water, health care, and sanitation are limited. As such, they are most prevalent in low-income 
countries, particularly among impoverished populations [19]. NTDs are not just diseases that coexist 
in poverty, they reinforce the cycle of poverty by negatively impacting worker productivity, physical 
growth, cognitive development, and school attendance [20,21]. Additionally, the morbidity 
associated with some of the NTDs lead to stigma, thereby affecting social relationships [22]. 
One billion people are thought to be infected by at least one NTD [19].  By some estimates, the 
health burden due to NTDs account for nearly 48 million disability-adjusted life years (DALYs) [23]. In 
comparison, the health burden due to tuberculosis, malaria, and HIV/AIDs is 49 million DALYs, 83 
million DALYs, and 82 million DALYs, respectively [23]. However, while HIV/AIDS, malaria, and 
tuberculosis account for more than 40% of the overseas development assistance (ODA) funding for 
health, collectively, NTDs receive just 0.6% of the ODA health funds [24]. Despite the 
disproportionate funding, investing in the control of NTDs is considered highly cost-effective, in part 
because many NTDs can be controlled or even eliminated through mass drug administration (MDA) 
to entire at-risk populations [25].  
1.2. Lymphatic Filariasis 
Lymphatic filariasis (LF) is an NTD endemic in 73 countries, with over a billion people considered as 
being at-risk of infection and an estimated 120 million people infected by the filarial nematodes 
Wuchereria bancrofti (> 90%), Brugia malayi, or B. timori [26]. Though most people infected remain 
asymptomatic, LF infection can result in debilitating and irreversible morbidity, typically manifested 
as moderate to extreme swelling of the lower limbs (lymphedema and elephantiasis), swelling of the 
scrotum (hydrocele), and acute adenolymphangitis (ADL) [9]. Once infected, treatment options are 
limited. Simple hygienic measures, antibiotics, and antifungals are used for managing lymphedema 
and elephantiasis. Antibiotics, antipyretics, and analgesics are used to alleviate ADL. For men 
suffering from hydrocele, however, surgery is among the only options [27]. Recent estimates put the 
health burden due to LF-related morbidity at 2.74 million DALYs (1.73m-4.00m) [4]. This estimate, 
however, only accounts for the direct physical burden of LF. Upon incorporating the mental health 
problems that often accompany LF-related morbidity, the health burden increases to 5.09 million 
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DALYs [28]. Further, lymphatic filariasis impacts worker productivity and, despite limited options for 
care, burdens health systems in endemic countries [29].  
1.2.1 Transmission of Lymphatic Filariasis 
Mosquitoes serve as the vector for LF, transferring infective L3 larvae to humans during the course 
of a blood meal. Upon entry into humans, the larvae mature into male and female worms that mate 
in the lymph nodes of their human hosts. From this point on, female worms are fecund, producing 
millions of microfilariae (mf) throughout their lifespan (estimated at 4-6 years or longer). The mf 
circulate in the peripheral blood of infected humans at times that correspond to the peak biting 
patterns of their primary mosquito vector – the exact species primarily belonging to the genera 
Anopheles, Culex, Mansonia, or Aedes, depending on the geographic locale. Once taken up in a blood 
meal and inside the mosquito, the mf pass through the midgut and develop into an L2 larvae stage 
followed by an infective L3 larvae stage, before being passed on to the next host where the cycle 
continues (Figure 1) [30]. 
Figure 1: Transmission cycle of Wucheria Bancrofti 
 
 
1. Introduction 
21 
 
1.2.2 Determination of Lymphatic Filariasis Endemicity 
The gold standard for determining populations at-risk for LF involves taking blood slides to assess the 
presence of circulating mf in a community [31]. However, the mf circulate in the blood at times that 
correspond to when the mosquitoes bite, which, in many areas, is only at night [32]. In such areas, 
blood slides to detect circulating mf need to be both collected and examined at night, which makes 
the use of blood slides for assessing endemicity highly inconvenient for both communities and 
mapping teams. Further, the sensitivity of blood slides vary by the accuracy of the person reading 
the slide, as well as the volume of blood collected [33]. To counter many of the challenges inherent 
in using blood slides, rapid tests have recently been introduced which allow for identification of 
infected individuals through blood samples that can be taken at any time of the day. In areas where 
W. bancrofti is thought to be endemic, the immunochromatographic card test (ICT) whole blood 
antigen card test can be used to detect infection, while the Brugia Rapid test can be used to detect 
antibodies from Brugia spp. infection [33,34].  
1.2.3 Global Distribution of Lymphatic Filariasis 
Mapping in areas thought to be endemic for LF have been carried out using both blood slides and 
rapid tests [31]. As of 2013, 44 out of 73 endemic countries had finished mapping surveys. With the 
exception of Eritrea, mapping is underway or completed in all other endemic countries [12]. 
Lymphatic filariasis is most common in tropical and sub-tropical regions, including Sub-Saharan 
Africa, the Western Pacific Region, Southeast Asia, and parts of Central and South America [12,31]. 
Transmission intensity is highly focal, with risk of infection increasing with increased temperature 
and rainfall and decreasing with altitude [31]. Figure 2 depicts areas where the environment is 
suitable for LF transmission [31], while Table 1 provides a breakdown of at-risk populations by World 
Health Organization (WHO) region [12]. In rural Africa, LF is most commonly transmitted by 
Anopheles mosquitoes, while in urban areas of Africa, as well as throughout Asia, Central and South 
America, Culex mosquitoes serve as the primary vector [35].  
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Table 1: LF at-risk population by WHO Region, 2013 
WHO Region Population at-risk for LF Percent of global at-risk population by region 
SEAR 
651,283,942 55% 
AFRO 
468,392,074 40% 
WPR 
26,499,057 2% 
EMR 
20,443,951 2% 
AMR 
12,048,009 1% 
Total 
1,178,667,033 
 
 
Figure 2: Map of environmental suitability for lymphatic filariasis transmission 
 
1.2.4 Prevention of Lymphatic Filariasis 
Annual administration of albendazole paired with ivermectin or diethylcarbamizine citrate (DEC) 
reduces circulating mf to levels that cannot sustain transmission. The feasibility of preventing LF is 
improved by the fact that the antifilarials can be distributed as mass drug administration (MDA) to 
all at-risk populations [9], and  through partnerships with Merck & Co., GlaxoSmithKline (GSK), and 
Eisai, which currently donate the ivermectin, albendazole, and DEC tablets used against lymphatic 
filariasis [10,11].  
1. Introduction 
23 
 
While not the primary strategy for prevention, vector control also plays a role in reducing LF 
transmission. The use of long-lasting insecticidal nets (LLINs) for the control of malaria has been 
shown to have an effect on LF transmission, especially where Anopheles mosquitoes serve as the 
primary vector [36]. Indoor residual spraying (IRS) in the Solomon Islands in the 1960s is also thought 
to have contributed substantially to the elimination of LF in the country [37]. The positive effects of 
vector control in combating LF are facilitated by the inefficiencies of LF transmission. In Yangon, 
Myanmar, where Cx. Quinquefasciatus is the primary vector, study teams estimated an average of 
15,500 infective bites to be required to result in one transmittable LF infection [38].  However, the 
extent to which LF transmission is reduced as a result of vector control still needs to be quantified 
[36]. 
1.2.5 The Global Program to Eliminate Lymphatic Filariasis 
In 1997, the International Task Force for Disease Eradication classified LF as a potentially eradicable 
disease due, in part, to the feasibility of interrupting transmission, the lack of a significant animal 
reservoir, and the availability of accurate diagnostic tools to assess infection [8,33,39]. Shortly 
thereafter, the World Health Assembly (WHA) adopted resolution WHA 50.29, which calls on 
Member States to develop national plans leading to the elimination of LF [9]. In response to the 
WHA resolution, the WHO began the Global Program to Eliminate Lymphatic Filariasis (GPELF) in 
2000 with the overall goal of eliminating LF as a public health problem by 2020. The GPELF aims to 
accomplish this through two stated objectives: (1) to stop the spread of infection (interrupt 
transmission); and (2) to alleviate the suffering of affected populations (control morbidity). The 
GPELF strategy for accomplishing the first objective centers around annual MDA with albendazole 
and either ivermectin or DEC to entire eligible populations living in areas where LF is endemic 
(defined as areas where prevalence of circulating mf or antigenemia is ≥1%) [9].  With five years 
remaining to achieve the targets, the GPELF still considers global elimination by 2020 to be 
achievable if all countries scale-up MDA coverage to 100% of their at-risk populations within the 
next one year, and by assuming five rounds of annual MDA to be sufficient to interrupt transmission 
in all areas [40].  
1.2.6 Progress of and challenges facing the Global Program to Eliminate Lymphatic 
Filariasis 
The GPELF is among the most rapidly expanding public health programs ever undertaken [41]. In the 
15 years since the GPELF began, more than five billion antifilarial treatments have been distributed, 
58 out of 73 endemic countries have conducted at least one round of MDA, and 15 countries are 
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currently conducting post-MDA surveillance to assess the interruption of LF transmission [12]. Since 
the inception of the GPELF, China and South Korea have also certified local elimination [42,43]. By 
some estimates, the population at-risk for LF has decreased by 46% under the GPELF [44], while the 
economic benefits from the first eight years of the program could be up to 21.8 billion US dollars 
(USD) [29].   
Though the GPELF has made great progress against LF, many at-risk populations remain untreated 
[12]. Issues with funding, logistics, community commitments and enthusiasm towards the program, 
natural and man-made disasters, civil and political unrest, and contraindications of the combination 
antifilarial treatments in areas where the parasitic disease Loa loa is highly endemic threaten the 
program [13,45,46]. Ensuring the timely distribution of the drugs used in the MDA program, 
achieving effective levels of treatment coverage, maintaining community support, and ensuring 
adequate numbers of trained community distributors to carry out the GPELF strategy pose 
additional challenge to achieving the program targets [46]. 
1.2.7 EpiFil 
EpiFil is a deterministic model composed of partial differential equations, which aims to capture the 
dynamics of LF transmission [15]. EpiFil has been previously used to assess the impact of 
interventions for LF and has been validated against data sets for transmission with Anopheles spp. in 
East Africa and by Culex spp. in Pondicherry, India [15,47-49].  The model is fully age-structured and 
also takes into account the probability of adult worms remaining unmated.  
The model incorporates changes in state parameters through the following partial differential 
equations: 
  
  
 
  
  
  
 
 
           
         
  
  
 
  
  
              
  
  
 
  
  
      
which includes the mean adult worm burden in humans (W), the mean microfilariae density in 
humans (M), and the mean level of immunity (I). The model also takes into account natural death of 
mf and adult worms. Incidence of hydrocele and lymphedema, as well as damage to the lymphatic 
system as a result of LF infection, are accounted also for.  A depiction of the model is shown in Figure 
3. 
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Figure 3: EpiFil 
 
A schematic of the deterministic model, EpiFil. W represents the mean worm burden in humans, M the mean 
mf density, and L the mean intensity of L3 larvae. Diagram courtesy of Stolk et. al[50] 
 
1.3 Disease eradication 
Disease eradication has been considered to be a fundamental example of a global public good [51]. 
Successfully eradicating a disease also represents a significant triumph in public health. Indeed, the 
eradication of smallpox, which remains the only human disease that has been successfully 
eradicated, is heralded as one of the greatest achievements of the 20th century [52,53]. Eradicating 
an NTD in particular has additional benefits, including gains towards equity and social justice [22].  
Disease eradication requires a high degree of international collaboration and coordination over a 
long period of time [54]. Indeed, in the Global Burden of Disease study, Murray pointed out that  
Whether eradication is achieved depends on the level of control adopted by the country that 
undertakes the least control. In practical terms, any country in which disease is endemic can 
prevent eradication from being achieved [55].  
Additional challenges facing disease eradication initiatives involve unforeseen circumstances, such as 
civil unrest, natural disasters, and disease epidemics that threaten the health systems’ capacities to 
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deliver the intervention [45]. The evolution of resistance to the drugs used in the intervention, the 
realization that interrupting transmission in some areas is biologically unfeasible, and problems in 
maintaining the long term investments required all pose challenges to disease eradication initiatives 
[56-58]. Until the disease is eradicated, there also remains a continual risk of imported cases back 
into previously disease-free areas [59]. If unsuccessful, disease elimination and eradication 
campaigns could represent a poor use of resources and lead to donor fatigue [57]. 
1.4 Eradication Investment Cases 
Given the many complex and interlinking issues involved in committing to a disease eradication 
initiative, decision makers, researchers, and thought leaders convened the 7th Ernst Strüngmann 
forum in 2009 in order to discuss the need for an evidence base in which to decide whether disease 
eradication initiatives should go forward. This meeting resulted in the concept of an Eradication 
Investment Case (EIC) [60].  
Since the forum, guidelines for the development of an EIC have since been put into place, which 
specify that an EIC should describe four primary components: (1) the proposed investment, which 
includes an analysis of the significance of the disease; an understanding of the current state of 
efforts against the disease; and considerations for how eradication could be achieved, (2) the 
rationale for investing, which takes into account the feasibility or reaching eradication; the health, 
social, and economic burden of the disease; an assessment of total costs; an analysis of the cost-
effectiveness of eradication; and considerations about the health systems; and (4) Issues to take into 
account when shifting to eradication, including partnerships and governance; monitoring and 
evaluation; and an operational research plan [61,62]. 
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2 Study rationale and aims 
Building from the momentum of successfully eradicating smallpox in 1980, the World Health 
Authority (WHA) called for the eradication of polio with resolution WHA 41.28 [63]. Three years 
later, resolution 39.21 was adopted, which called for the eradication of Dracunculiasis [64]. In 
response, global programs to reach eradication are underway for both diseases [65,66]. The 
campaigns for these initiatives were based on the realization that eradication was technically 
feasible, meeting three crucial objectives, including: the presence of a vaccine or other mode of 
preventing future infections, (2) lack of an animal reservoir, and (3) accurate diagnostics [67]. 
However, operational challenges encountered by both the polio and Dracunculiasis programs have 
underscored the importance of understanding a number of additional factors prior to undertaking 
an eradication program [62]. 
As such, this project was undertaken in order to create evidence for decision makers to determine 
whether to pursue LF eradication, and, if so, to what level of intervention intensity. Specifically, this 
work aimed to: 
 Predict the duration of MDA necessary to reach local elimination for a variety of 
transmission archetypes using an existing model of LF transmission 
 
 Develop plausible scenarios leading to global elimination and eradication under varying 
levels of MDA scale-up 
 
 Estimate the number of treatments required for each scenario 
 
 Estimate the potential economic and financial investment needed to interrupt LF 
transmission under each of the scenarios 
 
 Quantify the potential health impact of eradicating LF 
 
 Estimate the cost-effectiveness of different intensities of MDA scale-up 
 
 Project the potential savings to the health system as a result of averted LF-related morbidity 
 
 Value possible gains in worker productivity that could result from averted LF-related 
morbidity. 
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3.1 Abstract 
Background 
Lymphatic filariasis (LF) is a neglected tropical disease for which more than a billion people in 73 
countries are thought to be at-risk. At a global level, the efforts against LF are designed as an 
elimination program. However, current efforts appear to aim for elimination in some but not all 
endemic areas. With the 2020 goal of elimination looming, we set out to develop plausible scale-up 
scenarios to reach global elimination and eradication. We predict the duration of mass drug 
administration (MDA) necessary to reach local elimination for a variety of transmission archetypes 
using an existing model of LF transmission, estimate the number of treatments required for each 
scenario, and consider implications of rapid scale-up.  
Methodology  
We have defined four scenarios that differ in their geographic coverage and rate of scale-up. For 
each scenario, country-specific simulations and calculations were performed that took into account 
the pre-intervention transmission intensity, the different vector genera, drug regimen, achieved 
level of population coverage, previous progress toward elimination, and potential programmatic 
delays due to mapping, operations, and administration. 
Principal Findings  
 Our results indicate that eliminating LF by 2020 is unlikely. If MDA programs are drastically scaled up 
and expanded, the final round of MDA for LF eradication could be delivered before 2029 after 4,159 
million treatments. However, if the current rate of scale-up is maintained, the final round of MDA to 
eradicate LF may not occur until 2050.   
Conclusions/Significance 
Rapid scale-up of MDA will decrease the amount of time and treatments required to reach LF 
eradication. It may also propel the program towards success, as the risk of failure is likely to increase 
with extended program duration. 
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3.2 Author Summary 
Lymphatic filariasis (LF) is a disease caused by filarial worms transmitted by different types of 
mosquitoes that can lead to massive disability, including elephantiasis and hydrocele. LF has no 
significant zoonotic reservoir and is thought to be a potentially eliminable disease through once 
yearly treatment distributed by mass drug administration (MDA). In this study, we set out to 
determine how many treatments and over how much time it might take to globally eliminate and 
eradicate LF under different levels of treatment intensities. We created a model that took into 
account country-specific and disease-specific variables, and found that if the current intensity of 
MDA is maintained, 3,409 million treatments distributed over the next 37 years will be required. 
However, if treatment is rapidly expanded to the entire at-risk population in all endemic countries, 
eradication could be achieved with 4,159 million treatments and in less than half the time. While our 
estimates suggest more time may be needed to reach LF elimination than what is currently 
projected, with continued commitment, eradicating LF is within reach. 
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3.3 Introduction 
Lymphatic filariasis (LF) is a neglected tropical disease (NTD) primarily prevalent in poor populations 
in 73 countries [1]. LF is caused by infection with Wuchereria bancrofti, Brugia malayi, or B. timori 
transmitted by a variety of mosquito genera [2]. Infection with the filarial nematodes can damage 
the lymphatic vessels, the main clinical manifestations being lymphedema, hydrocele, and 
elephantiasis [3]. In addition to disfigurement and disability, people affected by LF face stigma, social 
adversity, and economic hardship [5-7]. 
LF is spread by mosquitoes that take up circulating microfilariae (mf) in the peripheral blood of 
infected humans [68]. Administration of albendazole with ivermectin or diethylcarbamazine citrate 
(DEC) has been shown to reduce circulating mf to such low levels that transmission cannot be 
sustained [9]. For this reason, LF is one of six diseases considered to be potentially eliminable [8]. 
Accordingly, in 1997 the World Health Assembly (WHA) adopted resolution WHA 50.29, which calls 
for the elimination of LF as a public health problem and, in 2000, the World Health Organization 
(WHO) established the Global Program to Eliminate Lymphatic Filariasis (GPELF). The GPELF aims to 
eliminate LF in all endemic countries by 2020 through annual mass drug administration (MDA) 
maintained over multiple years [9]. The program benefits through donations from Merck & Co. and 
GlaxoSmithKline (GSK), which have pledged to provide enough ivermectin and albendazole, 
respectively, to achieve elimination, as well as from Eisai, which in 2010, pledged 2.2 billion DEC 
tablets [10,11]. 
The GPELF has scaled up rapidly and is among the fastest growing disease elimination programs in 
the world [41]. By the end of 2013, 56 LF-endemic countries had carried out MDA, of which 15 are 
now undertaking post-MDA surveillance. In 2013 alone, more than 410 million anti-filarial 
treatments were distributed under the GPELF. However, the program is not without its challenges: 
mapping is incomplete in 12 countries, 14 countries requiring MDA are yet to begin, and many of the 
other countries are targeting relatively small proportions of their at-risk populations [12]. Issues with 
compliance, contraindications of ivermectin and DEC in areas with hyper Loa loa-endemicity, and 
interruptions in funding also plague the program [13,14]. At a global level, the efforts against LF 
could be considered a global elimination program (elimination of infection in some but not all 
countries) as the name suggests, or an eradication program (permanent reduction to zero of the 
worldwide incidence of infection) as implied by the stated aims of the program [12,40,69].  
In order to assist decision makers in determining whether efforts for LF should be scaled up to try to 
achieve eradication, it has been proposed to use an analytic and deliberate methodology to produce 
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evidence-based guidance on the rationale for investing [62,70]. As part of this endeavor, we herein 
predict the duration of MDA necessary to reach local elimination for a variety of transmission 
archetypes using an existing model of LF transmission, outline plausible scale-up scenarios leading to 
global elimination and eradication, and estimate the number of treatments required under each 
scenario. Potential delays in implementation, previous progress, and different intensities of infection 
and transmission are also taken into account. Studies on the economic and financial costs, the 
impact on disease burden, and cost-effectiveness of these scenarios are to be published as 
companion papers. 
3.4 Methods 
We have defined four hypothetical scenarios that differ in their geographic coverage and rate of 
scale-up. The global elimination scenario represents the case whereby countries continue with 
current practices. As such, it serves as the comparator against all other scenarios. The other three 
scenarios aim at reaching LF eradication through varying levels of MDA scale-up. Key assumptions 
and differences between the scenarios are outlined in Table 2. The number of years that each 
endemic country exceeded the minimum effective coverage rate of 65% in previous rounds of MDA, 
as well as the geographic coverage and rates of scale-up are provided in Table 3 (countries without 
previous rounds of MDA for LF) and Table 4 (countries that previously carried out MDA for LF). All 
scenarios were assumed to begin in 2014 and run until the final round of MDA has been distributed 
in each country under consideration. Though coverage rates above 65% are considered to be the 
lowest threshold necessary to be effective, the average programmatic coverage for countries that 
had previously achieved effective coverage was over 80%. Therefore, we assume that prospective 
MDA will continue to be performed at higher levels, and therefore assume MDA coverage to be fixed 
at 85%.  
 
 
 
 
 
3.  What is needed to eradicate lymphatic filariasis?  
A model-based assessment on the impact of scaling-up mass drug administration programs 
33 
 
Table 2: Key features of the proposed scenarios for global elimination and eradication of LF 
 Global 
Elimination 
(comparator) 
Eradication I Eradication II Eradication III 
Intervention MDA MDA MDA MDA 
Coverage 
rate 
85% 85% 85% 85% 
Countries 
considered 
All LF endemic 
countries that 
have previously 
conducted 
MDA
¥
 
All LF endemic countries
¥
, 
including all countries co-
endemic for L. loa 
All LF endemic 
countries
¥
, including 
all countries co-
endemic for L. loa 
All LF endemic 
countries
¥
, 
including all 
countries co-
endemic for L. loa 
Rate of scale-
up 
Countries with 
previous MDA 
continue at 
same rate as 
historically 
Countries with previous MDA 
continue at same historical 
rate, countries without 
previous progress begin at an 
‘average’ rate of MDA scale-
up (schedule II) 
Schedule I: All 
countries add 20% of 
their at-risk 
populations to the 
MDA schedule 
annually 
All countries  treat 
100% of their at-
risk populations 
annually 
¥Assuming country requires MDA  
Table 3: Countries without previous rounds of MDA for LF 
Country Primary 
vector 
Treatment
α
 At-risk population, 
2012
¤
 
Population 
growth rate, 
2012
¥
 
Scale-up 
schedule
±
 
Delay
§
 
Angola Anopheles IVM + ALB 12,090,000 3.1% -/2/1/0 4 
Brunei Darussalam Culex* DEC + ALB 15,000 1.4% -/2/1/0 1 
Chad Anopheles IVM + ALB 7,270,000 3.0% -/2/1/0 4 
Central African 
Republic 
Anopheles IVM + ALB 3,300,000 3.1% -/2/1/0 4 
Equatorial Guinea Anopheles IVM + ALB 420,000 2.8% -/2/1/0 1 
Eritrea Anopheles DEC + ALB 3,577,000 3.3% -/2/1/0 4 
Gabon Anopheles IVM + ALB 1,290,600 2.4% -/2/1/0 1 
Guinea Anopheles IVM + ALB 6,067,135 2.6% -/2/1/0 1 
New Caledonia Aedes DEC + ALB 12,378 1.6% -/2/1/0 1 
Palau Aedes DEC + ALB 20,044 0.7% -/2/1/0 1 
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Republic of the 
Congo 
Anopheles IVM + ALB 2,600,000 2.6% -/2/1/0 1 
São Tomé and 
Príncipe 
Anopheles DEC + ALB 410,000 2.7% -/2/1/0 1 
South Sudan Anopheles IVM + ALB 1,659,558 4.3% -/2/1/0 4 
Sudan Anopheles IVM + ALB 19,893,779 2.1% -/2/1/0 4 
The Democratic 
Republic of Congo 
Anopheles IVM + ALB 49,140,000 2.7% -/2/1/0 4 
The Gambia Anopheles IVM + ALB 1,200,000 3.2% -/2/1/0 1 
Zambia Culex DEC + ALB 8,780,000 3.2% -/2/1/0 4 
Zimbabwe Culex DEC + ALB 6,000,000 2.7% -/2/1/0 4 
*Treatment durations for Culex spp. were used for countries in which primary vector species was unknown. 
α
Treatment assumed to occur once annually using diethylcarbamazine citrate (DEC) and albendazole, or in 
areas co-endemic with onchocerciasis, ivermectin (IVM) and albendazole (ALB) 
¤
 Preventive Chemotherapy Databank Lymphatic Filariasis [Internet]. WHO. 2015 [cited 2015 January 20]. 
Available from: http://www.who.int/neglected_diseases/preventive_chemotherapy/lf/en/. 
¥ 
United Nations, Department of Economic and Social Affairs, Population Division (2013). World Population 
Prospects: The 2012 Revision, Key Findings and Advance Tables. Working Paper No. ESA/P/WP.227. 
±
 Refers to MDA schedules assumed to be used by these countries for the purposes of our analysis, for the 
global elimination scenario, eradication I, eradication II, and eradication III scenarios, respectively. In schedule I, 
two deciles (20%) of the at-risk population are added to the MDA schedule annually. In schedule II, one decile is 
added annually. In schedule III, one decile is added every 2 years, and in schedule IV, one decile is added every 
3rd year (see: Rate of Scale-Up and History of Control). ‘-‘ refers to a continued absence of an MDA program. ‘0’ 
refers to instantaneous scale-up. 
 
§
A 4-year delay was assumed for countries that have not completed LF mapping, while a 1-year delay was 
assumed for those that have completed mapping but have not previously carried out MDA. 
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Table 4: Countries that previously carried out MDA for LF 
Country Primary 
vector 
Treatment
α
 At-risk 
population, 
2012
¤
 
Population 
growth rate, 
2012
¥
 
Previous 
effective 
years
¤
 
Scale-up 
schedule
±
 
>50% targeted 
Burkina Faso Anopheles IVM + ALB 16,779,208 2.9% 11 1/1/1/0 
Cameroon Anopheles IVM + ALB 17,091,469 2.5% 5 1/1/1/0 
Côte d'Ivoire Anopheles IVM + ALB 14,000,000 2.3% 1 1/1/1/0 
Comoros Culex DEC + ALB 514,110 2.4% 5 1/1/1/0 
Egypt Culex DEC + ALB 536,443 1.7% 11 1/1/1/0 
Fiji Aedes DEC + ALB 529,984 0.8% 7 1/1/1/0 
French Polynesia Aedes DEC + ALB 274,544 1.1% 10 1/1/1/0 
Ghana Anopheles IVM + ALB 11,925,399 2.2% 11 1/1/1/0 
Haiti Culex DEC + ALB 10,732,356 1.4% 10 1/1/1/0 
India Culex DEC + ALB 617,170,000 1.3% 15 1/1/1/0 
Kenya Culex* DEC + ALB 3,421,741 2.7% 3 1/1/1/0 
Lao PDR Culex* DEC + ALB 132,644 1.9% 2 1/1/1/0 
Liberia Anopheles IVM + ALB 3,600,000 2.7% 0 1/1/1/0 
Malawi Anopheles IVM + ALB 14,807,685 2.9% 5 1/1/1/0 
Mali Anopheles IVM + ALB 16,166,882 3.0% 7 1/1/1/0 
Mozambique Anopheles IVM + ALB 17,114,949 2.5% 3 1/1/1/0 
Nepal Culex DEC + ALB 15,755,990 1.2% 10 1/1/1/0 
Niger Anopheles IVM + ALB 12,467,592 3.8% 4 1/1/1/0 
Philippines Aedes DEC + ALB 29,383,286 1.7% 9 1/1/1/0 
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Samoa Aedes DEC + ALB 186,649 0.8% 5 1/1/1/0 
Sierra Leone Anopheles IVM + ALB 6,667,687 1.9% 5 1/1/1/0 
Thailand Aedes DEC + ALB 73,495 0.3% 11 1/1/1/0 
Tuvalu Aedes DEC + ALB 10,373 0.2% 4 1/1/1/0 
Uganda Anopheles IVM + ALB 14,464,244 3.4% 5 1/1/1/0 
30-50% targeted 
Dominican 
Republic 
Culex DEC + ALB 249,803 1.3% 6 2/2/1/0 
Guyana Culex DEC + ALB 690,869 0.6% 2 2/2/1/0 
Indonesia Culex DEC + ALB 113,283,453 1.2% 7 2/2/1/0 
Myanmar Culex DEC + ALB 41,666,403 0.8% 9 2/2/1/0 
Timor Leste Anopheles DEC + ALB 1,180,067 2.9% 3 2/2/1/0 
United Republic 
of Tanzania 
Culex IVM + ALB 45,173,251 3.0% 11 2/2/1/0 
20-30% targeted 
Bangladesh Culex  DEC + ALB 77,230,000 1.2% 14 3/3/1/0 
Benin Anopheles IVM + ALB 3,747,913 2.7% 11 3/3/1/0 
Guinea Bissau Anopheles IVM + ALB 1,582,496 2.4% 1 3/3/1/0 
Malaysia Anopheles DEC + ALB 1,266,123 1.7% 7 3/3/1/0 
Nigeria Anopheles IVM + ALB 108,526,381 2.8% 5 3/3/1/0 
<20% targeted 
Brazil Culex DEC 1,700,000 0.9% 4 4/4/1/0 
Ethiopia *Culex IVM + ALB 30,000,000 2.6% 4 4/4/1/0 
Kiribati Culex DEC + ALB 103,058 1.5% 5 4/4/1/0 
Madagascar Anopheles DEC + ALB 18,602,379 2.8% 6 4/4/1/0 
Micronesia Aedes  DEC + ALB 11,241 0.1% 1 4/4/1/0 
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Papua New 
Guinea 
Anopheles DEC + ALB 5,602,188 2.2% 1 4/4/1/0 
Senegal Anopheles IVM + ALB 5,314,600 2.9% 3 4/4/1/0 
*Treatment durations for Culex spp. were used for countries in which primary vector species was unknown. 
α
Treatment assumed to occur once annually using diethylcarbamazine citrate (DEC) and albendazole (ALB), or 
in areas co-endemic with onchocerciasis, ivermectin (IVM) and albendazole (ALB) 
¤
 Preventive Chemotherapy Databank Lymphatic Filariasis [Internet]. WHO. 2015 [cited 2015 January 20]. 
Available from: http://www.who.int/neglected_diseases/preventive_chemotherapy/lf/en/. 
¥ 
United Nations, Department of Economic and Social Affairs, Population Division (2013). World Population 
Prospects: The 2012 Revision, Key Findings and Advance Tables. Working Paper No. ESA/P/WP.227. 
 
±
 Refers to MDA schedules assumed to be used by these countries for the purposes of our analysis, for the 
global elimination scenario, eradication I, eradication II, and eradication III scenarios, respectively. In schedule 
I, two deciles (20%) of the at-risk population are added to the MDA schedule annually. In schedule II, one 
decile is added annually. In schedule III, one decile is added every 2 years, and in schedule IV, one decile is 
added every 3rd year (see: Rate of Scale-Up and History of Control)..  ‘0’ refers to instantaneous scale-up. 
 
 
3.4.1 Scenario Development 
Scenarios were developed by first reviewing the WHO preventive chemotherapy (PCT) databank to 
assess progress made towards LF elimination as of 2012 [12]. The scenarios were further refined, 
with key assumptions agreed upon in a series of technical advisory group meetings, including 
stakeholders from WHO, Centers for Disease Control and Prevention (CDC), funders, pharmaceutical 
companies, and program managers from endemic countries.  
In the global elimination scenario, countries that have not yet started will not start, and countries 
that have started continue according to their assigned level of scale-up (see: Rate of Scale-Up). In the 
eradication I scenario, countries that have already started MDA continue as in the global elimination 
scenario and countries that have not yet started implement MDA following an ‘average’ level of 
scale-up. The eradication II scenario represents the case in which all countries scale-up MDA more 
quickly (fast). Eradication III serves as the ‘best case’ scenario, whereby all endemic countries 
provide MDA to their entire at-risk populations immediately. Thus, this analysis provides insight into 
the differences in the amount of time and treatments required to extend elimination efforts to all 
endemic countries (eradication I), increase MDA intensity (eradication II) and, most ideally, scale-up 
instantaneously (eradication III).  
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3.4.2 Assumptions Regarding Interventions and Loiasis Co-Endemicity 
An important assumption underlying this study is that annual MDA using DEC with albendazole, or, 
in onchocerciasis-endemic countries, ivermectin and albendazole, will be sufficient to reduce 
circulating mf enough to interrupt the transmission cycle of LF if maintained for an appropriate 
number of years. Therefore, hardly predictable features that could undermine success, including 
systematic non-compliance with MDA, but particularly events such as civil unrest and humanitarian 
emergencies (e.g. earthquakes in Haiti and Nepal; Ebola epidemic in West Africa) that could 
compromise the health system’s capacity, could not be accounted for. We also assume that 
countries undertake MDA without interruption.  
Administration of ivermectin to communities with high prevalence (>40%) of L. loa is 
contraindicated, as the microfilaracidal actions of the drug poses an unjustifiably high risk of causing 
severe adverse events. As such, the WHO provisionally recommends the LF program to instead treat 
these areas with albendazole monotherapy distributed bi-annually  and vector control [71]. Here we 
assume that this strategy will be equally efficacious as annual albendazole-ivermectin, and thereby 
assume the number of years of MDA required in areas co-endemic with L. loa to be equivalent to the 
number of years required with albendazole-ivermectin.  
3.4.3 Rate of Scale-Up and History of Control 
The GPELF advises LF endemic countries to conduct MDA for 4-6 years [9]. This duration only holds 
at a country level if all endemic areas are treated simultaneously. To incorporate scaling-up of 
geographic coverage for each scenario, we divided each country’s at-risk population into deciles, and 
assumed MDA to start in subsequent deciles after varying durations according to four schedules of 
scale-up. In schedule I (fast), 20% of the at-risk population is added to the MDA schedule annually. In 
schedule II (average), one decile is added each year, in schedule III (slow) one decile is added every 
two years and in schedule IV (very slow) this period is three years. 
In the global elimination scenario, scale-up is based upon the proportion of the at-risk population 
each country previously targeted. In order to be allocated to schedule I, the at-risk population 
targeted in the most recent round of MDA had to exceed 50%. Schedule II has been assigned to 
countries previously targeting 30-50%, schedule III to those targeting 20-29.9%, and schedule IV to 
those targeting <20%. Rather than attempting to recreate the progress of each country exactly, we 
used these categories to incorporate a range of scale-up levels encountered. Previous progress 
made towards local elimination was further taken into account by counting the number of 
previously effective years of MDA, which was considered as any year in which program coverage 
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within the targeted area (regardless of the at-risk population targeted) exceeded 65%. We then 
subtracted the number of effective years previously achieved from the number of years of MDA 
deemed necessary (see below: Transmission Archetypes; Table 5) in order to determine the number 
of years of MDA remaining. 
3.4.4 Delays 
For all scenarios, we assume that countries that have finished mapping but not begun MDA have a 1-
year delay, whereas countries that have not completed mapping nor begun MDA have a 4-year 
delay. While countries face challenges of different magnitudes and require different durations to 
map, the 4-year delay assumed corresponds to the average number of years that mapping took in 
countries with available data to support the calculation [12]. 
3.4.5 Prevalence Data 
To account for heterogeneity in transmission intensity within countries, we obtained paired baseline 
circulating filarial antigenemia prevalence, measured through immunochromatographic test (ICT), 
and mf prevalence data from sentinel site surveys from program countries across the AFRO region. 
As specified by the WHO, these surveys involve collecting fingertip blood, between 10 p.m. and 2 
am. from at least 300 participants aged five years and above [72]. We gained additional access to ICT 
prevalence data from mapping studies in 17 African countries. The relationship between mf and ICT 
prevalence was estimated using the non-parametric regression proposed by Passing and Bablock, 
which assumes linearity and uncertainties in both variables [73]. The regression equation calculated 
from the paired prevalence data was then used to infer mf prevalence from the ICT mapping data. 
We determined the percentage of the at-risk population that fell into prevalence quartiles: <5%, 5-
10%, 10.1-15%, >15%, for each country that provided district level prevalence data. To account for 
uncertainties in this approach, we took 500 random draws from a multinomial distribution with 
probabilities based on weighted averages from the dataset and assumed these to be the possible 
ranges of pre-intervention prevalence distributions for all countries in our analysis.  
3.4.6 Transmission Archetypes 
It has been theoretically demonstrated that the required duration of MDA is region-specific and 
dependent on various factors, including drug regimen and level of coverage, vector species, and pre-
intervention transmission intensity [74-76]. In order to broadly capture the heterogeneous 
transmission patterns of LF, we defined transmission archetypes (Table 5). In addition to prevalence 
levels and drug regimens, we accounted for differences in transmission between Anopheles spp. and 
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Culex spp., which notably differ in their mf-density dependent likelihood of becoming infected [77]. 
Predicting regional anopheline- or culicine-mediated LF transmission has been shown to require 
different model formulations and parameterizations [78]. For our analysis we made several 
simplifications: we assumed transmission of W. bancrofti by Aedes spp. was similar to transmission 
efficacy by Culex spp., while transmission of Brugia spp. was assumed to be comparable to 
W. bancrofti transmission by Anopheles spp. Where the primary vector was unclear, infection by 
Culex spp. was assumed in order to avoid underestimating the number of MDA rounds required.  
Table 5: Estimates of the number of annual MDA rounds needed to reach local LF elimination by 
transmission archetypes, based on sets of 500 simulations using EpiFil and assuming 85% 
coverage. 
Primary vector Treatment
α
 Baseline MF prevalence 
5% 10% 15% 20% 
Anopheles spp. DEC + ALB 6 6 7 7 
IVM + ALB 7 9 11 11 
Culex spp. DEC + ALB 9 10 11 11 
IVM + ALB 11 13 15 15 
α
Treatment assumed to occur once annually using diethylcarbamazine citrate (DEC) and albendazole (ALB), or 
in areas co-endemic with onchocerciasis, ivermectin (IVM) and albendazole (ALB) 
The number of rounds corresponds to the minimum at which at least 97.5% of simulations went to elimination. 
 
 
3.4.7 Modeling the Number of MDA Rounds Required to Reach Local Elimination 
The duration of MDA required to eliminate LF was predicted for the transmission archetypes using a 
deterministic model of LF transmission, EpiFil [15]. The model used for the current analysis has been 
described in detail, validated against multiple data sets for both transmission settings with 
Anopheles spp. and Culex spp., and used extensively to predict LF intervention outcomes 
[15,47,49,79]. Details on model structure, equations, and the approach to obtaining parameter 
estimates are provided in Supplementary material 1. 
For all transmission archetypes, we ran 500 simulations of once-yearly MDA of varying total 
durations, drawing from a range of parameter estimates. The lowest number of rounds at which the 
95th percentile range of the simulations resulted in an mf prevalence below 1% 50 years after the 
start of the MDA program was taken as a conservative measure of the number of rounds required to 
ensure elimination.  
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3.4.8 Calculating the Number of Future Treatments Required 
Population at-risk figures were taken from the WHO PCT database for 2012 and adjusted for 
population growth using country-specific 2012 United Nations estimates [12,80]. MDA coverage 
rates were assumed to be 85% for all countries. Except for areas co-endemic with L. loa, treatments 
are assumed to occur annually.  Based on the pre-intervention prevalence distributions, we 
developed 500 estimates of the number of treatments needed for each country and scenario. 
Results are reported as the mean number of treatments by region and scenario, along with 95% 
credible intervals. 
Role of the funding source 
The study sponsor had no role in study design; in the collection, analysis, and interpretation of data; 
in the writing of the report; and in the decision to submit the paper for publication. 
3.5 Results 
Our results indicate that interrupting LF transmission in all countries by 2020 is unlikely, though if 
MDA is drastically scaled-up and expanded, the final round of MDA to eradicate LF could be carried 
out by 2028 (eradication III; Figure 4). If scale-up continues at the current rate, as modeled in our 
global elimination and eradication I scenarios, the last round of MDA will not be given until 2050, 
largely due to slow scale-up in areas where transmission occurs through Culex spp. The eradication II 
scenario reaches the last round of MDA by 2032. As this scenario assumes that all countries add 20% 
of their at-risk populations to MDA annually, the last countries to reach local elimination are those 
that were delayed due to mapping, and whose vector and treatment combination included 
Anopheles spp. and ivermectin or Culex spp. and DEC, including: Angola, Chad, the Democratic 
Republic of Congo, South Sudan, Sudan, Zambia, and Zimbabwe. Figure 5 provides a visual 
representation of the impact different intensities of scale-up and expansion have on time to reach 
local elimination for each country. 
Figure 4: Cumulative number of treatments by year 
Figure 5: Maps depicting the final year of MDA per country for the four scenarios 
Since the scenarios take into account population growth, rapid scale-up of MDA also decreases the 
number of treatments required. As depicted in Figure 6, the eradication III scenario initially requires 
substantially more treatments, but by 2024, the treatments under this scenario are projected to be 
less than that required under all other scenarios. The global elimination scenario is projected to 
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require approximately 3,409 million treatments (95% CI: 3,185m–3,538m). Expanding the program 
to all endemic countries will increase the number of treatments to 4,666 million (95% CI: 4,419m–
4,904m). Scaling-up MDA more rapidly, as under the eradication II scenario, results in savings of 
nearly 300 million treatments compared to the eradication I scenario. Under the most optimistic 
scenario (eradication III), eradication could be achieved with 4,159 million treatments (95% CI: 
3,924m–4,382m). As shown in Figure 4, this represents nearly 750 million treatments more than the 
global elimination scenario but 210 million treatments less than the intensified eradication scenario 
(eradication II). Owing to the largest burden, the AFRO region requires the majority of treatments, 
followed by Southeast Asia. With the shift from global elimination to eradication, the number of 
treatments required in the Eastern Mediterranean region increases by more than 380 fold due to 
treatments required for Sudan, which is not considered under the elimination scenario (Table 6).  
Figure 6: Incremental treatment projections by year (elimination as comparator) 
Table 6: Projected treatment needs (in millions) by WHO region with 95% credible intervals 
 Global Elimination 
(comparator) 
Eradication I Eradication II Eradication III 
AFRO 2,117 (2,011–2,223) 3,202 (3,048–3,355) 2,930 (2,788–3,074) 2,746 (2,605–2,889) 
SEAR 1,148 (1,102–1,190) 1,148 (1,102–1,190) 1,141 (1,096–1,183) 1,139 (1,096–1,181) 
WPR 109.3 (104.5–114.0) 109.7 (104.9–114.4) 100.1 (95.6–104.7) 98.55 (94.25–102.94) 
AMR 34.66 (33.07–36.27) 34.66 (33.07–36.27) 33.43 (31.87-35.00) 33.10 (31.60–34.62) 
EMR 0.3729 (0.3380–0.4095) 173.0 (165.2–180.9) 164.1 (156.6–171.5) 142.0 (134.2–150.2) 
Total 3,409 (3,185–3,538) 4,667 (4,419–4,904) 4,369 (4,133–4,594) 4,159 (3,924–4,382) 
 
3.6 Discussion 
As not all LF endemic countries are considered under the global elimination (comparator) scenario, 
any eradication campaign will require a massive increase in treatments. However, if LF is to be 
eliminated in all endemic countries, then rapid scale-up as soon as possible will lead to increased 
savings – both in terms of time and treatments. Accelerated MDA may also propel the program 
towards success, as risk of failure (due to lapses in funding, donor fatigue, or occurrence of 
calamitous events) potentially increases with extended program duration [81]. It is conceivable that 
a decrease in program duration may also decrease the likelihood of drug resistance evolution [56]. 
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Noticeably missing from our analysis is India. While India has the greatest burden of LF [4], it has 
made substantial progress against the disease, having distributed nearly 3.5 billion antifilarial 
treatments since 2001 [12]. As such, our model suggests that further rounds may not be necessary 
for India. However, previous studies have found pockets of systematic non-compliance in India, 
leading to MDA coverage in those areas to fall below effective coverage [82]. It is therefore possible 
that transmission of LF may still occur in India. However, in order to remain consistent in our 
approach, and in recognizing that to provide global estimates we cannot take into account all 
eventualities, additional treatments for India have not been considered.  
We sought data from a number of diverse sources. Due to the inherent structure of the LF program, 
however, our analysis relies heavily on data that have been collected and reported directly by each 
country. While this arrangement raises a number of issues, discrepancies in the data could also 
decrease the validity of our estimates. Inconsistencies in coverage data may affect the number of 
years required to interrupt transmission, while inaccuracies in at-risk estimations would directly 
impact the number of treatments projected to reach our scenario endpoints. Whether these issues 
would result in underestimates or overestimates is dependent upon the direction and magnitude of 
the error. 
While we avoided underestimating scale-up potential through our eradication III scenario, it is 
possible that we overestimated the capacity of some countries to scale-up. It is possible that we also 
overestimated the effectiveness and ability to proceed with rapid scale-up in areas co-endemic with 
L. loa. While WHO has provisional guidelines for dealing with LF and L. loa co-endemicity, no such 
areas have been broadly targeted for LF elimination as yet, and thus the effectiveness and feasibility 
of the strategy remains unclear. At the same time, the mass distribution of long-lasting insecticidal 
nets (LLINs) in many malaria endemic sites is likely to have a large impact on LF transmission by 
anophelines [36,83]. Because the impact remains difficult to quantify, and uncertainty remains 
regarding the duration LLINs have to remain in place, we have not included this here. The time and 
treatment estimates in this study are based on data and model formulations and parameterizations 
currently available to the authors. Many of the assumptions and simplifications inherent to our 
scenarios are in need of closer investigation. Ideally, models would be fit to specific transmission 
settings within and between countries, as parameter values have been shown to differ by region 
[47]. Other aspects equally deserving of more attention, but likewise beyond the scope of this 
project, are the effectiveness of twice-yearly albendazole in concert with vector control for areas co-
endemic with L. loa, and the consequences of mid-program delays, [84,85]. Care should thus be 
taken when interpreting these results, particularly at a country-specific level.  
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Our duration estimates are considerably longer than those proposed under the GPELF, which 
envisages all endemic countries to reach full geographic coverage by 2016, with post-MDA 
surveillance in all countries anticipated by 2020 [40]. While this level of scale-up is similar to that 
proposed under our eradication III scenario, we project the last round of MDA to occur nearly a 
decade later, in 2028. This divergence arises from differences in the assumed number of rounds of 
MDA required to interrupt transmission. Depending on baseline prevalence and vector-treatment 
combinations, our model estimates interruption in transmission to occur after 6-15 rounds of MDA 
(Table 4). In contrast, the GPELF assumes five years of MDA in all areas [40]. It is worth noting that 
the durations in this study represent a potentially conservative measure, as they were based on the 
95th percentile range of simulations leading to elimination, accounting for the uncertainty in our 
parameter estimates. This measure was taken to represent the time that could guarantee 
elimination with a reasonable level of certainty, but does not preclude that shorter durations may be 
sufficient in many areas. However, the discrepancy between predicted MDA durations and those 
advocated by GPELF was also evident in previous estimates with both deterministic and stochastic LF 
transmission models [50]. While aggressive goals for disease elimination and eradication potentially 
propel campaigns forward, overly optimistic projections could stifle innovations and further 
investment, ultimately hindering the initiative.  
This study adds to the growing body of evidence on the feasibility of eliminating LF. While our 
estimates suggest more time may be needed to reach LF elimination than what is currently 
projected, the treatment estimates for our scenarios represent 66-89% of that which has already 
been distributed under the GPELF. Thus, our analysis indicates that with continued commitment, 
eliminating LF is within reach. 
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Figures 
Figure 4: Cumulative number of treatments by year 
 
The line with circular markers represents the global elimination (comparator) scenario. As highlighted in the 
text boxes, both the global elimination and eradication I scenario are estimated to conclude MDA after 37 
years of MDA. Eradication II, the intensified scale-up scenario, sees the last round of MDA to occur by 2032, 
after 19 years of MDA. Eradication III is estimated to require 15 years of MDA, concluding in 2028. 
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Figure 5: Maps depicting the final year of MDA per country for the four scenarios 
 
The global LF elimination scenario does not include countries that have not yet begun MDA. 
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Figure 6: Incremental treatment projections by year (elimination as comparator)  
 
All eradication scenarios see an increase in the number of treatments after 4 years as the result of the imposed 
delay for countries that have not previously finished mapping or begun MDA. By 2024, the eradication III 
scenario requires less treatments than the global elimination (comparator) scenario, and from 2028, the 
eradication II scenario is also projected to require fewer treatments than elimination. 
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4.1 Abstract 
Introduction 
Lymphatic filariasis (LF), a neglected tropical disease (NTD) preventable through mass drug 
administration (MDA), is one of six diseases deemed possibly eliminable. Using previously developed 
scenarios and treatment projections, we present the projected financial and economic costs of 
global elimination and eradication. 
Methodology/Key Findings 
Costing was undertaken from a health system perspective, with all results expressed in 2012 US 
dollars. A discount rate of 3% was applied to calculate the net present value of future costs.  
Prospective NTD budgets from LF endemic countries were reviewed to preliminarily determine 
activities and resources necessary to undertake a program to eliminate LF. In consultation with LF 
program experts, activities and resources were further reviewed and a refined list of activities and 
necessary resources, along with their associated quantities and costs, were determined and grouped 
by activity: advocacy, capacity strengthening, coordination and strengthening partnerships, data 
management, ongoing surveillance, monitoring and supervision, drug delivery, and administration. 
The cost of mapping and undertaking transmission assessment surveys have also been incorporated 
into the financial estimates. The value of donated drugs as well as volunteer time of the community 
drug distributors were combined with the financial costs to determine the economic costs. 
The elimination scenario, which includes countries that previously undertook MDA, is estimated to 
cost 929 million USD (884m-972m). Proceeding to eradication is anticipated to require a higher 
financial investment, estimated at 1,235 million USD (1,172m-1,300m) in the eradication III scenario 
(immediate scale-up), with eradication II (intensified scale-up) projected at 1,274 million USD 
(1,209m-1,331m), and eradication I (slow scale-up) estimated at  1,289 million USD (1,227m-
1,340m). The economic costs of the eradication III scenario are estimated at approximately 7.57 
billion USD (7.12bn-7.94bn), while the global elimination scenario is projected to have an economic 
cost of 5.21 billion USD (4.91bn-5.45bn). Countries in the AFRO region will require the greatest 
investment to reach global elimination or eradication, but also stand to gain the most in cost savings. 
Across all scenarios, capacity strengthening and advocacy represent the greatest financial costs, 
whereas strengthening partnerships, data management, mapping, post-MDA surveillance, and 
administration comprise the least. 
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Conclusions/Significance 
Though challenging to implement, our results indicate that financial and economic savings are 
greatest under the eradication III scenario. Thus, if eradication for LF is the objective, accelerated 
scale-up is projected to be the best investment.  
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4.2 Author Summary 
Lymphatic filariasis (LF) is a neglected tropical disease (NTD) that is thought to be potentially 
eradicable through once yearly mass drug administration (MDA) using drugs that are currently 
donated to LF endemic programs by the drug manufacturers. MDA has been proven to be a cost-
effective and efficient method of disease control, both for LF and other NTDs.  Previously, we 
developed scale-up scenarios of varying magnitude to reach global elimination (elimination of LF in 
all countries that have previously undertaken MDA) and eradication (local elimination of LF in all LF 
endemic countries) and determined the number of associated treatments that would be necessary 
in each country in each scenario. Here we project the costs – both financial and economic – of each 
of these scenarios. We use data from a myriad of sources to determine the cost of various activities, 
and found that training and advocacy activities comprise the bulk of the expenditure necessary. 
Among all scenarios, global elimination requires the least total investment. However, in terms of LF 
eradication, faster rates of scale-up is associated with a decrease in costs.  
 
 
  
4.  How much will it cost to eradicate lymphatic filariasis?  
An analysis of the financial and economic costs of intensified efforts against lymphatic filariasis 
53 
 
4.3 Introduction 
Neglected tropical diseases (NTDs) are a heterogeneous group of helminthic, bacterial, viral, fungal 
and protozoan infections that cause chronic and debilitating disability [19]. However, research and 
development to combat NTDs have notoriously been underfunded [86]. NTDs persist in areas where 
access to clean water, hygienic conditions, and health care are limited. As such, they are most 
prevalent in low-income countries [19]. Indeed, more than 70% of countries with endemic NTDs are 
classified as low-income or lower middle-income economies [87]. Infection with an NTD may affect 
cognitive and physical development and can result in permanent physical disability. Therefore, NTDs 
do not just coexist in poverty, they further propagate the cycle of poverty by hindering economic 
potential [20,21].  
Lymphatic filariasis (LF), an NTD, can result in irreversible and incapacitating disability, most often 
manifested as elephantiasis, lymphedema, and hydrocele [9]. With more than a billion people at-risk 
and 120 million people thought to be infected across 73 countries [26], LF is estimated to account 
for 2.74 million disability-adjusted life years (DALYs) (1.73m-4.00m)[4]. When incorporating the mild 
and moderate depression associated with LF-related disability, the health burden due to LF may be 
upwards of 5 million DALYs [28].  
However, LF is inefficiently transmitted, with an estimated 15,500 infective mosquito bites thought 
necessary to generate one transmittable infection [38]. LF is also preventable through once yearly 
treatment with antifilarials distributed through mass drug administration (MDA) [9]. This, coupled 
with the fact that LF does not have a significant animal reservoir, led the International Task Force on 
Disease Elimination to classify LF as a potentially eradicable disease [8,39]. In response, the World 
Health Organization (WHO) began the Global Program to Eliminate LF (GPELF), which aims for the 
global elimination of LF by 2020 [9]. In the fifteen years since the inception of the GPELF, great 
progress against LF has been made, with more than five billion antifilarial treatments distributed in 
58 endemic countries [12].  
Successfully eradicating a disease has innumerable long-term health benefits, and is also a classic 
example of a global public good [58,70,88]. Eradicating an NTD, like LF, has additional societal 
benefits, including improvements towards equity, fairness, and social justice [22]. However, disease 
elimination and eradication initiatives require substantial social and political commitments, as well 
as significant financial and economic investments. Given the increasingly intense competition for 
global health resources, the decision on where to invest funds needs to be based upon solid 
evidence [62].  This is particularly the case for investments and commitments made on a global 
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scale. In order to provide evidence to decision makers about the investment required to globally 
eliminate and eradicate LF, we used a micro-costing approach to analyze the financial and economic 
costs of interrupting LF transmission in all endemic countries under varying levels of MDA intensity, 
as well as the subsequent costs of conducting post-MDA surveillance.  
4.4 Methods 
4.4.1 Scenarios 
We previously developed scenarios to reach global elimination (elimination of infection in countries 
that have previously undertaken MDA) and eradication (elimination of infection in all endemic 
countries) of LF, taking into account previous progress made under the GPELF, pre-intervention 
prevalence levels, and possible delays in program implementation. The global elimination scenario 
maintains the current geographic expansion and rate of MDA scale-up as seen under the GPELF, and 
thus serves as the comparator scenario. The eradication scenarios were developed to assess the 
impact of expanding MDA to all endemic countries at an average level of scale-up (eradication I), 
intensifying efforts against LF (eradication II), and treating all endemic populations immediately 
(eradication III). Key components inherent in each scenario are outlined in Table 7 and a full 
explanation of all the scenario can be found in Chapter 3. 
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Table 7: Key features of the proposed scenarios for global elimination and eradication of LF 
 Global 
Elimination 
(comparator) 
Eradication I Eradication II Eradication III 
Intervention Annual MDA* Annual MDA* Annual MDA* Annual MDA* 
Coverage rate 85% 85% 85% 85% 
Start year 2014 2014 2014 2014 
Countries 
considered 
All LF endemic 
countries that 
have previously 
conducted MDA
¥
 
All LF endemic 
countries
¥
, including all 
countries co-endemic 
for L. loa 
All LF endemic 
countries
¥
, including all 
countries co-endemic 
for L. loa 
All LF endemic 
countries
¥
, 
including all 
countries co-
endemic for L. 
loa 
Rate of scale-up Countries with 
previous MDA 
continue at 
same rate as 
historically 
Countries with previous 
MDA continue at same 
rate as historically, 
countries without 
previous progress begin 
at ‘average’ rate (10% 
of at-risk population 
added to MDA schedule 
annually) 
All countries add 20% 
of their at-risk 
populations to MDA 
schedule annually 
All countries 
treat 100% of 
their at-risk 
populations 
annually 
Estimated final 
year of MDA 
2050 2050 2032 2028 
Number of 
treatments 
necessary 
(millions) 
3,409  
(3,185-3,538) 
4,667 
(4,419-4,904) 
4,369 
(4,133-4,594) 
4,159 
(3,924-4,382) 
*
Except in areas where L. loa prevalence exceeds 40%. 
 ¥
Assuming country requires MDA  
 
4.4.2 Timeframe and number of treatments required 
To determine the duration of MDA required for the different drug regimens, vector species, and pre-
intervention prevalence levels, we used EpiFil [15], a deterministic model of LF transmission. The 
amount of time and number of treatments required to reach the endpoints in each scenario are 
detailed in Chapter 3. Briefly, we considered the number of MDA rounds that each country had 
previously achieved a programmatic coverage of at least 65% (the minimum coverage necessary to 
be considered effective) between 1999 and 2012. Next, we subtracted the number of rounds of 
MDA required to reach local elimination from the number of previously effective years. Assuming 
once-annual MDA (aside from areas co-endemic with hyper Loaisis; see:  Assumptions about L. loa 
endemic areas), we then determined the number of future treatments needed for each country 
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under each scenario, accounting for the number of people at-risk, country-specific growth rates, 
duration of MDA necessary, historical rates of scale-up, and previous progress towards local 
elimination. By assuming that the populations at-risk for LF increase exponentially with population 
growth rates, scenarios with longer durations were also assumed to require more treatments (Table 
7). 
4.4.3 Approach used for costing 
To assess how much governments and donors would need to invest in order to implement the GPELF 
strategy to reach the global elimination and eradication of LF, we adopted a micro-costing, bottom-
up approach from the perspective of the health system of each LF endemic country. In contrast to 
gross-costing, which assesses average level costs from the top down, micro-costing may improve the 
accuracy of results by capturing resources and costs at the unit level [89].  
The costs associated with each scenario have been assumed to begin in the year 2014 and run until 
the final post-MDA transmission assessment survey (TAS) has been completed in each country under 
consideration. All results are listed in 2012 US dollars (USD) and, in the baseline analysis, future costs 
were discounted at 3%. One-way sensitivity on discount rates and probabilistic sensitivity analyses 
for all costing and quantity parameters were also explored. 
4.4.4 Data 
Line items from USAID’s NTD Master Plan Costing Tool in the African Region for Benin, Cameroon, 
Democratic Republic of Congo, Eritrea, Guinea, Madagascar, Niger, Senegal, and Sierra Leone 
ranging from January 2011 to April 2012 were reviewed to preliminarily determine essential 
activities and associated resources necessary for a country to successfully undertake a program to 
eliminate lymphatic filariasis (PELF). In consultation with key LF implementers from the PELF in 
Uganda, which has successfully been carrying out the GPELF MDA strategy since 2002 [12], all 
activities and resources were further reviewed and a refined list of core activities, necessary 
personnel, components, and resources, along with their associated costs, were ascertained.  
4.4.5 Activities considered 
We took into account the cost of advocacy; capacity strengthening; coordination and strengthening 
partnerships; mapping; data management; administration; ongoing surveillance; monitoring, 
evaluation, and supervision; drug delivery; and post-MDA transmission assessment surveys (TAS). As 
described below, the costs of increased surveillance in areas with meso L. loa prevalence, as well as 
the added expenditure of biannual MDA in hyper loaisis areas were also accounted for.  
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Advocacy was assumed to include the development and distribution of educational messages, as 
well as community meetings and sensitization activities with district and community leaders, sub-
county and parish supervisors, and community drug distributors (CDDs). Capacity strengthening 
comprised trainings on MDA procedures for national trainers, district trainer of trainers, sub-county 
and parish supervisors, community leaders, CDDs and teachers. Trainings for monitoring sentinel 
and spot check sites as well as trainings for M&E officers were also considered under capacity 
strengthening. Conference attendance and international exchanges, cross-border meetings for 
regional strategies towards controlling NTDs, NTD secretariat meetings, and technical committee 
meetings were assumed under coordination and strengthening partnerships. Data management 
included all activities involved with the acquisition and distribution of MDA data, including cleaning, 
entering, and analyzing.  The maintenance of sentinel sites – including equipment for administering 
microfilaria (mf) surveys and internal quality control tests – as well as the administration of sentinel 
and control site impact assessment surveys, associated data collection, and survey feedback 
meetings were grouped under ongoing surveillance. M&E included the supervision of MDA activities, 
monitoring for severe adverse events (SAEs), and regular feedback meetings at the district and 
national level. Drug delivery involved drug transport from the central stores to district stores and 
then onward to parish supervisors. Supplies to CDDs, including t-shirts and stationary, were also 
accounted for under drug delivery. Administration included overhead costs, the maintenance of 
office space, salaries to LF staff, and the procurement of necessary equipment.   
Mapping and TAS were assumed to include a preliminary visit, Immunochromatographic card test 
(ICT) testing, data collection, and feedback meetings. The cost of mapping was included for any 
country that, as of 2012, had not yet completed mapping nor started MDA. In order to determine 
the costs of post-MDA surveillance on a global level, all TAS have been assumed to be school-based. 
Moreover, TAS have been assumed to occur in each district (see Determination of resource 
quantities for assumptions about district size) after the final estimated round of MDA (as determined 
through earlier modeling exercises) and twice thereafter at three year intervals. The number of TAS 
conducted has thus been assumed to vary by the number of districts achieving the specified number 
of MDA rounds, though the quantities of resources required for each individual TAS was assumed to 
remain constant.   
Assumptions about Loa loa endemic areas 
Previous studies indicate that individuals harboring more than 30,000 L. loa microfilaria per milliliter 
of blood are put at unacceptably high risk of developing severe adverse events (SAEs) if administered 
ivermectin or DEC [13,90,91].  As L. loa prevalence within a community has been shown to have a 
4.  How much will it cost to eradicate lymphatic filariasis?  
An analysis of the financial and economic costs of intensified efforts against lymphatic filariasis 
58 
 
close correlation with individual L. loa mf density, provisional GPELF guidelines recommend 
communities endemic with LF that also have a L. loa prevalence greater than 40% be treated with bi-
annual MDA using albendazole monotherapy coupled with vector control [71].  
Mapping studies to determine areas of co-endemicity between LF and L. loa, however, are not yet 
complete. While we recognize that not all populations at-risk for L. loa are also at-risk for LF, for the 
purposes of this study, we make the assumption that the percentage of mapped areas from RAPLOA 
studies that were found to have 20-39.9% (meso) or >40% (hyper) L. loa prevalence corresponds 
directly to the percentage of the population in these countries also at risk for LF [12,92]. In assessing 
the costs for undertaking the LF program in these areas, we further assume the cost of vector 
control to be covered by other initiatives. In line with the provisional recommendations, we assume 
that the population of people living in hyper-endemic areas will receive bi-annual albendazole 
through MDA. Financially, this is assumed to double the costs of data management and drug delivery 
in these areas. For populations in meso-endemic regions of L. loa, once yearly albendazole and 
ivermectin is still presumed. In areas of both hyper and meso L. loa, the costs associated with 
monitoring for SAEs are assumed to increase two-fold. 
4.4.6 Determination of resource quantities 
In line with the approach for assessing necessary activities, quantities and duration of use for each 
required component were established through consultation with key members from the Ugandan 
PELF team. Aside from program activities with inherently fixed costs, budgeted line items were 
assumed to vary linearly by the size of the population to be treated (see below: Timeframe and 
number of treatments required). In the baseline analysis, we have assumed that the number of 
resources required to carry out the PELF for a certain population in Uganda is relatively similar to the 
number of resources required to carry out the program for a population of similar size in other LF 
endemic countries. As MDA in Uganda is implemented at a community level, the amount of 
resources and duration of activities required to successfully complete the PELF in Uganda are 
generally organized by district, sub-county, and village units. In order to standardize the at-risk 
population falling into the different administrative divisions across all LF endemic countries, the 
average number of people at-risk for LF in each district, sub-county, and village were determined for 
Uganda and then assumed for all LF-endemic countries.  
4.4.7 Determination of financial costs  
Using detailed expenditure budgets from the Ugandan PELF as a reference, unit costs for other LF 
endemic countries were estimated by adjusting for country-specific comparative price levels (i.e., 
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purchasing power parity (PPP) adjusted exchange rates) for all local, non-tradable goods and services 
[93]. Tradable goods were assumed to already be at market value and were thus left unadjusted. 
Retail prices from established vendors were used for tradable goods, including laboratory supplies 
and capital items. The WHO CHOICE database was used for unit costs which were unable to be 
determined elsewhere, as well as for salaries of LF personnel, including: the NTD director, LF 
program manager, administrative assistant, finance officer, data manager, and supplies manager 
[16]. As the African Program for Onchocercaisis Control (APOC) uses a strategy similar to that 
employed by the GPELF [94], line items in our study were validated against similar line items found 
in APOC approved budgets. Table 8 provides a list of the primary activities considered in calculating 
the financial costs, as well as the average cost per district in the base case. 
Table 8: Average costs per district, base case 
 
Activity 
 
Average costs per district 
(standard deviation) 
Advocacy  
Community meetings $8,946.96 ($686.11) 
Social mobilization – District leaders $469.95 ($18.30) 
Social mobilization – Sub-county supervisors $256.39 ($20.12) 
Social mobilization – Parish supervisors, CDDs, community leaders $8,821.35 ($753.30) 
Workshop for creating messages $5.61 ($0.22) 
Dissemination of health messages $916.44 ($54.62) 
Capacity Strengthening  
Training national trainers, MDA and M&E $14.31 ($0.54) 
Training of district Trainers of trainers, MDA and M&E $800.35 ($31.22) 
Training of sub-county supervisors, MDA and M&E $754.87 ($50.60) 
Training of parish supervisors and community leaders, MDA and M&E $20,991.65 ($2,141.29) 
Training of CDDs $15,848.40 ($1,655.98) 
Training of teachers $4,748.92 ($520.45) 
Training for monitoring sentinel and spot check sites $690.36 ($49.50) 
Training M&E officers $1,310.23 ($56.96) 
Coordination and strengthening partnerships  
Conference attendance and international exchanges $83.04 ($1.16) 
Attend cross-border meetings for LF and NTDs $141.62 ($1.69) 
NTD secretariat meeting $81.81 ($3.35) 
Technical committee of NTDs $38.28 ($1.71) 
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Data management 
Cleaning, entering, analyzing data $119.54 ($6.96) 
Transfer of data from field to head office $704.69 ($93.39) 
Ongoing surveillance  
Maintain sentinel sites $1,616.73 ($8.80) 
Site survey – data collection $3,000.23 ($94.92) 
Site survey – feedback meetings $1,589.09 ($36.39) 
Transmission assessment surveys – preliminary visit $1,165.08 ($40.04) 
Transmission assessment surveys – data collection $2,849.99 ($55.82) 
Transmission assessment surveys – feedback meeting $1,438.37 ($35.32) 
Monitoring, evaluation, and supervision  
Supervision of MDA $18,216.02 ($485.16) 
Feedback meetings at district level $884.54 ($37.36) 
Feedback meetings at national level $19.34($0.53) 
Drug delivery  
Supplies for CDDs $3,924.54 ($485.62) 
Drug transport $3,078.94 ($180.55) 
Administration  
Overhead costs $377.36 
Salaries, LF staff $950.19 ($51.04) 
Procurement of necessary equipment and software $61.63 ($2.23) 
  
4.4.8 Determination of economic costs 
Economic costs, which were assumed to encompass financial costs as well as the value of volunteer 
time and donated pharmaceuticals, were also estimated in order to have a more comprehensive 
understanding of the projected investment needed to globally eliminate and eradicate LF [95]. A 
schematic of the algorithm used for calculating the financial and economic costs is depicted in Figure 
7. 
Figure 7: Financial and economic costing algorithm 
Value of donated pharmaceuticals 
The opportunity costs of the donated drugs used in the GPELF were accounted for by valuing each 
400 mg tablet of albendazole at $0.19, 50 mg tablet of diethylcarbamazine citrate (DEC) at $0.0025, 
and 3 mg tablet of ivermectin at $0.50, which were the suggested manufacturer prices prior to being 
donated [96-98]. An additional economic cost of $0.0018 was assumed to be the value of each tablet 
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for insurance and shipping costs, which also are currently absorbed by the drug manufacturers [98]. 
While the WHO specifies each treatment to include either 6 mg DEC/kg of body weight or 150 µg 
ivermectin/kg of body weight plus 400 mg ALB, for the purposes of this global level exercise, we 
assume all annual MDA treatments to be comprised of one tablet of ALB with either three tablets of 
ivermectin or seven tablets of DEC. 
Value of volunteer time  
The value of donated time was evaluated by correlating the time CDDs were presumed to volunteer 
under each scenario with country-specific or, when necessary, region-specific daily per worker 
agriculture wage estimates taken from the World Bank’s World Development Indicators Online, 
inflated to 2012 [17]. Two CDDs were assumed to be sufficient to dispense MDA in each village [99]. 
Drawing from the results of previous time studies, CDDs were assumed to volunteer 5.5 days on 
mobilization and sensitization, 4.6 days conducting pre-MDA census activities, and 17.8 days on drug 
distribution [100]. 
4.4.9 Uncertainty Analysis 
To account for the uncertainty in our model parameters, we conducted a probabilistic sensitivity 
analysis (PSA) involving all financial costs and quantities. We assumed 10% variance and utilized 
gamma distributions for all parameters to avoid negative values [101]. As the covariance between 
parameters was unknown, we further assumed all parameters to be independent. For all scenarios, 
we ran the model for 500 iterations for every year in every country. The model outputs thus provide 
a distribution of cost results, reported as mean estimates and associated 95% credible intervals. 
Supplementary material 2 has additional details involved in conducting the PSA. 
Role of the funding source 
The study sponsor had no role in study design; in the collection, analysis, and interpretation of data; 
in the writing of the report; and in the decision to submit the paper for publication. 
4.5 Results 
The total financial investment to implement the global elimination scenario is projected at 929 
million USD (883m-972m). To expand the campaign to all endemic countries at an average rate of 
scale-up (eradication I scenario) would require 1,289 million USD (1,227m-1,345m), an increase of 
about 360 million USD (346m-374m) over the global elimination scenario (Figure 8). The decrease in 
scenario duration inherent in the eradication II scenario (intensified scale-up) comes with decreased 
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costs, estimated at 1,274 million USD (1,209m-1,331m), while instantaneously scaling up MDA to all 
LF endemic countries is projected to require an investment of 1,235 million USD (1,172m-1,300m).  
The AFRO region accounts for 62-68% of the financial costs, with Southeast Asia requiring between 
22-30% of the projected investment (Table 9).  
Table 9: Total financial costs by region 
 Global Elimination 
(comparator) 
Eradication I Eradication II Eradication III 
AFRO $ 573.5 
(546.8-599.7) 
$ 877.8 
(840.6-914.8) 
$ 870.7 
(832.9-906.7) 
$ 840.1 
(801.5-877.0) 
SEAR $ 278.0 
(266.3-289.1) 
$ 278.0 
(266.3-289.1) 
$ 279.3 
(266.7-291.7) 
$ 279.2 
(265.8-292.1) 
WPR $ 56.35 
(54.68-57.90) 
$ 66.80 
(65.12-68.35) 
$ 57.75 
(56.05-59.43) 
$ 54.40 
(52.64-56.14) 
AMR $ 20.92 
(20.37-211.5) 
$ 20.92 
(20.37-21.50) 
$ 19.06 
(18.41-19.71) 
$ 18.33 
(17.71-18.96) 
EMR $0. 4403 
(0.4328-0.4503) 
$ 45.92 
(43.60-48.07) 
$ 46.67 
(44.34-48.92) 
$ 42.90 
(40.29-45.63) 
Total $ 929.2 
(890.5-965.4) 
$ 1,289 
(1,239-1,337) 
$ 1,273 
(1,223-1,322) 
$ 1,235 
(1,183-1,284) 
 
Figure 8. Incremental financial costs (global elimination scenario as comparator) 
Providing MDA to the entire at-risk population immediately, as assumed under the eradication III 
scenario, requires a significant initial investment, but within 10 years’ time, the annual cost of 
implementing the scenario becomes less than the alternatives (Figure 9). The sharp increase in 
financial costs four years from the start of the eradication III scenario corresponds to the start of 
MDA to all at-risk populations in countries that were previously delayed due to mapping. 
Figure 9: Financial costs by year, discounted at 3% 
The average unit financial cost for undertaking each of the scenarios ranges from 0.27 USD in the 
global elimination scenario to 0.31 USD in both the eradication II and III scenarios. However, as the 
scenarios progress, the unit costs increase substantially. This is due to the fact that the number of 
people to be treated (the denominator of the estimate) decreases, though the cost associated with 
some of the core activities – including coordination and strengthening partnerships, administration, 
and data management – are assumed to remain relatively constant. As an example of this, Figure 10 
depicts the unit financial costs seen under eradication I, which, by 2050, extend to more than 1,700 
USD per person treated.  
Figure 10: Financial cost per person treated, eradication I 
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Capacity strengthening proves to be the most costly activity, representing between 53-55% of the 
overall financial costs, while advocacy (22-24%); ongoing surveillance (6%); monitoring, evaluation, 
and supervision (8%), and drug delivery (9%) account for most of the remaining costs (Table 10). 
Table 10: Percentage of financial costs by activity 
 Global 
Elimination 
Erad I Erad II Erad III 
Advocacy 24% 22% 23% 24% 
Capacity strengthening 53% 55% 55% 53% 
Coordination and strengthening partnerships <1% <1% <1% <1% 
Data management <1% 1% 1% 1% 
Ongoing surveillance 6% 6% 6% 6% 
Monitoring, evaluation, and supervision 8% 8% 8% 8% 
Drug delivery 9% 9% 9% 9% 
Post MDA Surveillance <1% <1% <1% <1% 
Administration <1% <1% <1% <1% 
Mapping - <1% <1% <1% 
 
To highlight the increased costs due to the assumed increase in expenditure for data management, 
drug delivery, and monitoring and evaluation, Figure 11 graphically depicts the financial costs of 
treating a population of 1 million at-risk for LF in the Democratic Republic of Congo. Costs of 
mapping and post-MDA surveillance are not included in this plot. Areas of meso L. loa are 
anticipated to only result in an increase in monitoring and evaluation, thereby having little effect on 
the overall costs. In comparison to a population of comparable size without L. loa, hyper L. loa 
endemicity is associated with an increase of approximately 15% in the overall costs of the program. 
Figure 11: Financial costs of L. loa endemicity for a population of one million in the Democratic 
Republic of Congo 
When the economic costs are considered, the costs of all scenarios are substantially higher (5.2 
billion USD for the global elimination scenario). Extending the coverage to all endemic countries is 
estimated to require around 7.9 billion USD (7.5bn - 8.3bn), or 45% more than global elimination 
scenario. Depending on the scenario, between 48-53% of the economic costs are due to the value of 
the donated drugs (Figure 12). 
Figure 12: Economic costs by component, discounted at 3% 
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When discounted at 0%, 3%, or 5%, the eradication III scenario represents the least expensive 
investment  of all of the eradication scenarios, though, when discounting the financial and economic 
costs by 5%, the eradication I scenario becomes marginally more cost saving compared to the other 
eradication scenarios (Table 11). 
Table 11: Financial and economic costs by discount rates (in millions) 
 Global Elimination Eradication I Eradication II Eradication III 
Financial costs     
0% $1,170 $1,697 $1,542 $1,445 
3% $929.2 $1,289 $1,274 $1,235 
5% $814.3 $1,098 $1,132 $1,112 
Economic costs     
0% $6,616 $10,618 $9,773 $8,853 
3% $5,212 $7,940 $8,000 $7,565 
5% $4,5067 $6,645 $7,357 $6,821 
 
4.6 Discussion 
This study is the first to estimate the financial and economic investments required to globally 
eliminate or eradicate lymphatic filariasis. The projected economic cost of global elimination is 5.2 
billion USD, about half of which is due to the value of the donated drugs. These results serve to 
further highlight the crucial partnership between the GPELF and the drug donation programs. While 
the cost to globally eliminate LF is less than that to eradicate, it must be recognized that deciding to 
pursue elimination rather than eradication signifies the continuation of LF-related costs indefinitely, 
and comes at a health burden to populations that remain untreated. 
A comparison of our costs against other costs is important for validation, though challenging due to 
differing methodologies. Though not inclusive of overhead costs, a study from two states in Nigeria 
found the cost associated with conducting MDA for the prevention of LF to cost between 0.02 USD 
and 0.12 USD [102].  A multi-country costing study conducted by Goldman et. al found financial costs 
to range from 0.06 USD in Burkina Faso to 2.23 USD in Haiti [98]. A separate study in Haiti reported 
the cost per person treated to be 1.44 USD [103]. Thus, in comparison to other MDA costing studies, 
our average unit financial cost estimates are well within the range of previously reported studies. 
With a dearth of evidence on the costs of implementing morbidity management programs [104], and 
given that the aim of our study was to assess the costs of interrupting transmission of the causative 
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agent of LF, we did not include the costs of morbidity management in our estimates. Our analysis 
also does not take into account the cost for certifying elimination on a country level nor the activities 
involved in globally assessing whether eradication has been achieved. As currently experienced by 
the Global Polio Eradication Initiative, the costs for finding and ascertaining the last cases to reach 
eradication are substantial [66,105]. While our analysis does not consider the costs associated with 
finding the last cases of LF infection, the unit costs for the final populations treated in the 
eradication I scenario are orders of magnitude higher than the average unit costs – beyond 1,700 
USD per person treated. It has previously been recognized that when the cost of disease eradication 
becomes within reach, the unit costs associated with prevention become decreasingly attractive. 
However, at that point, it is crucial not to lose momentum, nor investment, otherwise there is great 
risk of failure [57,106]. Developing realistic cost projections from the start of the program could help 
mitigate the risk of donor fatigue towards the endgame of disease eradication. Further, when 
disease eradication is within reach, shifting the focus from unit costs per person treated to the costs 
per case averted may also help to sustain global commitments [107]. 
Our analysis found an increase in financial costs of 15% to treat a hyper endemic L. loa area in the 
DRC. This estimate does not take into account increases in advocacy in these areas, which may be 
necessary to achieve the targeted levels of coverage. Further, the costs for medical transport and 
additional medications that might be needed to treat patients suffering from severe adverse events 
have not been incorporated in this analysis. Costing studies for such post-MDA response activities 
have not previously been carried out, though such costs are likely to vary by the incidence of SAEs, 
the geographic location, and the intensity of response required. If substantial and significant 
response is required in many areas, the overall costs for implementing the eradication scenarios 
would certainly result in higher costs than projected in this baseline study. 
A number of methodological uncertainties in our study must be mentioned. Country-specific cost 
data was mostly unavailable and, consequently, was largely imputed from Ugandan data. By 
extrapolating cost data across countries and regions, we inherently made the assumption that each 
LF endemic country implements the GPELF strategy as in Uganda (for example, using volunteer 
CDDs, similar amount of trainings, etc.). Moreover, we assumed that the number of resources 
required to carry out the PELF for a certain population in Uganda remains relatively constant 
(varying by +/-10%) both across time and across countries. Ideally, LF-specific expenditure data 
would have been collected in all 72 LF-endemic countries. However, 14 of these endemic countries 
have never carried out MDA for LF [12]. Moreover, undertaking a study that accurately collected 
such data would potentially begin to rival the time and cost of running the PELF programs in many of 
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the countries to begin with. Thus, despite the large number of assumptions inherent in our 
approach, our costing model allowed for the development of comparable cost estimates on a 
country, regional, and global level.  
We conducted a probabilistic sensitivity analysis in order to overcome some of the limitations 
inherent in our costing parameters. In order to provide more robust estimates on the costs of 
achieving global elimination and eradication, costing studies in areas with the highest burden of LF 
could be undertaken in order reduce the level of uncertainty in costs. While improved cost data 
could be used to inform policy and improve planning, the cost of acquiring additional data should be 
weighed against the value of such data [108]. An additional use for the results found in our 
economic analyses, therefore, could be to assess the value of additional investments for LF, 
including the collection of expenditure data, as well as investments in diagnostics, drugs, and 
surveillance tools to help advance LF eradication. 
Our findings on the costs to globally eliminate and eradicate LF represent very achievable 
investments. Our cost estimates would have likely been even lower, though, if we assumed some 
level of integration or cost-sharing between other disease initiatives. Many countries have, in fact, 
integrated similar activities across vertical programs, including onchocerciasis, trachoma, and 
schistosomiasis, and others have paired drug delivery for MDA with other community distribution 
campaigns, including insecticide treated nets (ITNs) for malaria and ongoing vaccine programs. In so 
doing, the overall costs per program, indeed, generally decreased and efficiency reportedly 
improved [36,86,109-111]. Additionally, given the cost involved with each round of MDA, it could be 
cost saving to undertake TAS sooner in order to assess whether the interruption of transmission had 
been achieved. However, this approach could pose to be a difficult balance, since prematurely 
stopping MDA could result in resurgence of infection [112], ultimately leading to an increase in the 
cost of reaching eradication.  
Knowing the global costs of the program will help decision makers assess the feasibility and rationale 
of investing in LF eradication, while helping to facilitate planning and the development of strategies 
and policies. However, successfully eradicating LF depends on more than the monetary investment. 
Political will, continued community ownership, and the feasibility of the campaign all need to be 
taken into account [61]. However, if successful, disease eradication not only results in innumerable 
long-term health benefits, but also savings to the health system, gains in productivity, and 
improvements in social justice [22,29]. The decision of whether disease eradication should be 
pursued, therefore, needs to be approached with a comprehensive understanding of the many 
complex issues at play.  
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Figure 7: Financial and economic costing algorithm 
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Figure 8: Incremental financial costs (global elimination scenario as comparator) 
 
  
Figure 9: Financial costs by year, discounted at 3% 
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Figure 10: Financial cost per person treated, eradication I  
 
Figure 11: Financial costs of L. loa endemicity for a population of one million in the Democratic 
Republic of Congo 
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Figure 12: Economic costs by component, discounted at 3% 
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5.1 Abstract 
Background 
A program to eliminate lymphatic filariasis (LF) is underway, yet two key programmatic features are 
currently lacking: extension of efforts to all LF endemic countries, and expansion of geographic 
coverage of mass drug administration (MDA) within countries. For varying levels of scale-up of MDA, 
we assessed the health benefits and the incremental cost-effectiveness ratios (ICERs) associated 
with LF eradication, projected the potential savings due to decreased morbidity management needs, 
and estimated household productivity gains as a result of reduced LF-related morbidity. 
Methods 
We extended an LF transmission model to track hydrocele and lymphedema incidence in order to 
obtain estimates of the disability-adjusted life years (DALYs) averted due to scaling up MDA over a 
period of 50 years. We then estimated the incremental cost-effectiveness ratios (ICERs) and the cost-
effectiveness acceptability curves associated with different rates of MDA scale-up. Health systems 
savings were estimated by considering the averted morbidity, treatment seeking behavior, and 
morbidity management costs. Gains in worker productivity were estimated by multiplying estimated 
working days lost as a result of morbidity with country specific per-worker agricultural wages. 
Findings 
Our projections indicate that dramatically scaling-up MDA could lead to 4.38 million incremental 
DALYs averted over a 50 year time horizon compared to a scenario which mirrors current efforts 
against LF. In comparison to maintaining the current rate of progress against LF, dramatically scaling-
up MDA in order to pursue LF eradication, was most likely to be cost-effective above a willingness to 
pay threshold of 70.5 USD/DALY averted. Intensified MDA scale-up was also associated with lower 
incremental cost-effectiveness ratios. Health systems savings of intensive MDA scale-up was 
estimated up to 483 million USD. Extending coverage to all endemic areas could generate additional 
economic benefits through gains in worker productivity between 3.41 and 14.4 billion USD. 
Interpretation 
In addition to ethical and political motivations for scaling-up MDA rapidly, this analysis provides 
economic support for increasing the intensity of MDA programs. 
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5.2 Introduction 
To date, smallpox is the only human infectious disease that has been eradicated through deliberate 
efforts, an accomplishment that is considered among the greatest medical achievements in the last 
century [52,53]. This success increased interest in disease eradication as a public health strategy, and 
eradication campaigns against polio and Dracunculiasis are currently underway [65,81]. Progress 
against Dracunculiasis indicates that the concept of eradication can be applied to parasitic infections 
for which vaccines are not available [65].  
Disease eradication results in the permanent interruption of transmission of the causative agent of 
the disease and the ultimate disappearance of the organism as a free-living biological species. This is 
distinct from elimination, which is the interruption of transmission in a defined geographic locale. 
Control reflects the use of interventions aimed at reducing the health burden associated with 
transmission of a pathogen, but does not intend to interrupt transmission [69]. The decision to shift 
from a strategy based on reducing the health burden to one of elimination or eradication is not to be 
taken lightly [113]. Because eradication is an all-or-nothing achievement, and one that will require 
an intensified and/or altogether different strategy than disease control, failure to achieve it may 
represent a misuse of resources. In addition, failed attempts can lead to donor fatigue with 
persistent negative consequences [57]. To provide policy makers with guidance on whether to 
pursue eradication, the concept of an Eradication Investment Case (EIC) was developed following 
insights from an Ernst Strüngmann forum on scientific advances in disease eradication [60,70]. An 
EIC is expected to include a quantitative assessment of the technical and biological feasibility of 
achieving eradication, an assessment as to whether the health system infrastructure is capable of 
delivering the interventions, and evidence of sufficient funding and political will to support such a 
program. The various components also need to be periodically re-evaluated as the program 
progresses, since all are potentially prone to erosion due to factors including emerging drug 
resistance, weak health systems, or public and donor fatigue [67]. 
Further arguments for or against eradication may come from economic considerations [114]. Using a 
game-theoretic approach to the eradication of smallpox, Barrett & Hoel were able to specify 
conditions under which an eradication strategy was optimal. Specifically, when eradication was 
possible, high levels of control were never optimal [115]. Similar arguments based on health 
economic modeling have been made to support continued investments in the eradication of polio 
[116].  
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Lymphatic filariasis (LF) endemicity is strongly tied to poverty [117] and leads to debilitating, chronic 
forms of morbidity, most notably hydrocele and lymphedema [9]. The health burden from LF is 
considerable, estimated at 2.74 million disability-adjusted life years (DALYs) (1.73m-4.00m) in 2010 
[4]. Beyond affecting physical health and productivity, LF-related morbidity also leads to stigma and 
social exclusion, and impacts mental well-being [22]. 
Preventive chemotherapy represents the primary strategy of the ongoing Global Program to 
Eliminate Lymphatic Filariasis (GPELF), which aims for the global elimination of LF by 2020. The 
strategy is based on once-yearly mass drug administration (MDA) either with diethylcarbamazine 
citrate (DEC) and albendazole (ALB), or, in areas where onchocerciasis is also endemic, ivermectin 
(IVM) and ALB. These compounds kill microfilariae and affect the survivorship and fecundity of adult 
worms. If MDA is provided to a large proportion of the population (>65%) for a sufficient number of 
years, interruption of transmission in the targeted region is thought to be feasible [9]. 
As LF proceeds towards global elimination, certain challenges are worthy of consideration, including 
the feasibility of reaching remote populations and the ability to maintain coverage in urban areas 
with dense and mobile populations [46]. An animal reservoir is not generally thought to contribute 
to LF transmission, although Brugia malayi is sometimes found in non-human primates, cats, and 
dogs . For the purposes of this study we assume that eradication of LF is feasible and the mentioned 
challenges not insurmountable. 
We previously developed scenarios that could lead to global elimination or eradication of LF, 
estimated the time it might take to reach elimination and eradication, projected the number of 
treatments required under each scenario, and considered the associated financial and economic 
costs (Chapters 3 and 4). In the current study, we assess the health impact in terms of DALYs 
averted, estimate the cost-effectiveness associated with different intensities of scaling-up MDA, and 
project the possible savings to the health system and potential increase in worker productivity due 
to averted LF-related morbidity for each of these scenarios.  
5.3 Methods 
5.3.1 Scenarios modeled 
We defined four scenarios named global elimination, eradication I, eradication II, and eradication III, 
which differ in their geographic coverage and rate of MDA scale-up. The scenarios were developed in 
an iterative consensus process involving leading scientists, policy makers, program managers and 
other stakeholders following an analysis of the ongoing GPELF (Chapter 3). For areas co-endemic 
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with Wuchereria bancrofti and Loa loa we made the simplifying assumption that whatever strategy 
will end up being used in reality (e.g., the provisional guidelines from the WHO suggest bi-annual 
MDA of ALB and vector control) can be approximated in our model by annual MDA with IVM+ALB. 
The current global elimination scenario is defined as the comparator scenario, mirroring the rate of 
MDA scale-up seen under the GPELF thus far, but assumes that countries that have not yet begun 
MDA programs will not do so. As we identified low levels of geographic coverage within certain 
endemic areas to be the major impediment to progress against LF, the three eradication scenarios 
explore the impact of expanding MDA to all LF endemic populations at varying rates. Eradication I 
models the impact of expanding MDA to all endemic areas at the historical average rate of scale-up; 
eradication II assumes countries scale-up geographic coverage by 20% increments each year, and 
eradication III represents the best-case scenario, whereby all countries expand coverage to their 
entire at-risk population immediately. See Supplementary material 3 and Chapter 3 for further 
details. 
5.3.2 Estimates of disability-adjusted life years  
We used a deterministic model, EpiFil [15], to simulate filariasis transmission by either Anopheles 
spp. or Culex spp. vectors, following Gambhir & Michael [49]. See Supplementary material 3 for 
details on how the estimate was expanded to include chronic disease states. 
We translated the incidence of chronic disease to DALYs, which, in the case of LF, are composed of 
the years of life lived with a disability (YLD) multiplied by the disability weight (DW). We determined 
the number of new hydrocele and lymphedema cases in a given time period and assigned YLDs at 
that point based on the individual’s remaining life expectancy [118]. Per convention, no distinction in 
the DW was made between lymphedema and hydrocele, and symptomatic cases were assigned a 
DW of 0.11 [119]. Age-weighting was not considered in this study, but DALYs were discounted at 3% 
per year. Further details on the calculations are provided in Supplementary material 3. The DALYs 
were estimated for a period of 50 years to capture the long-term health benefits of interrupting 
transmission.  
5.3.3 Estimates of financial costs 
The financial costs of implementing the GPELF strategy in all LF endemic countries were estimated 
using a bottom-up approach from the perspective of an LF-endemic country’s health system, with 
future costs discounted at 3%. Activities considered in the cost estimates included advocacy; 
capacity strengthening; coordination and strengthening partnerships; data management; ongoing 
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surveillance; monitoring, evaluation and supervision; drug delivery; and administration. Costs for 
mapping, running post-MDA transmission assessment surveys and increased surveillance in areas of 
L. loa prevalence were also taken into account. A summary of the costing methodology (Chapter 4) is 
provided in Supplementary material 3. 
5.3.4 Cost-effectiveness analysis  
In order to evaluate the cost-effectiveness of eradication, the DALY projections for each country in 
each scenario were paired with country-specific financial cost estimates. With the global elimination 
scenario as the reference case against which all other scenarios were compared, cost-effectiveness 
was assessed using incremental cost-effectiveness ratios (ICERs). For each simulation, the monetary 
net benefits (MNB) were calculated as the mean incremental DALYs averted multiplied by the 
decision makers’ maximum willingness to pay for a DALY averted minus the mean incremental cost 
for the scenario [101]. Cost-effectiveness acceptability curves were used to graphically depict the 
probability for each scenario to be cost-effective at various willingness-to-pay thresholds. 
5.3.5 Impact on health services use and associated cost savings  
To assess the potential health systems savings due to averted morbidity management, we followed 
the approach of Chu et al. and assumed that on average 40% (20-50%) of hydrocele patients and 
50% (30-55%) of lymphedema patients seek treatment annually. We further assumed acute 
adenolymphangitis (ADL) to occur about twice per year (0-7 times) in 70% (45-90%) of hydrocele 
patients, and four (0-7 times) times annually for 95% (90-95%) of patients with lymphedema [29]. 
Health systems savings were then estimated by combining the averted incidence of morbidity, 
frequency of ADL episodes, and treatment seeking behavior paired with country-specific costs for a 
20 minute consultation at a primary health center with 50% population coverage [29]. Parameter 
uncertainty was considered by taking 500 random estimates within each parameter range, assuming 
normal distributions for treatment seeking behavior and triangular distributions for ADL episodes.  
5.3.6 Estimates of worker productivity gains 
Using a pre-established methodology, we also determined the impact that LF eradication could have 
on worker productivity [29].  To assess the potential worker productivity increase, we assumed ADL 
episodes to last four days on average (1-9 days), and cause a 75% (50-93%) reduction in productivity 
for their duration. LF-related morbidity was assumed to decrease the amount of productive working 
days by 15% (13-17%) for hydrocele patients and 20% (15-22%) for those with lymphedema. Three 
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hundred working days were assumed for those without LF-related morbidity. We monetarily valued 
possible gains in worker productivity by taking the number of working days lost due to LF-related 
morbidity paired with country-specific (when available) or region-specific daily per-worker 
agriculture wages given by the World Bank’s World Development Indicators Online [17], inflated to 
2012. Uncertainty in the parameter estimates was incorporated by drawing 500 random samples 
from each range assuming normal distributions.  
Role of the funding source 
The study sponsor had no role in study design; in the collection, analysis, and interpretation of data; 
in the writing of the report; and in the decision to submit the paper for publication. 
5.4 Results 
5.4.1 Estimates of disability-adjusted life years  
The intensity of MDA scale-up greatly impacts population health (Figure 13). With global elimination 
as the comparator, extending MDA to all endemic countries (eradication I) results in approximately 
1.72 million DALYs averted (95% Credible Interval (CrI): 1.09m-2.62m) over a 50 year time horizon. In 
contrast, intensifying geographic coverage in all countries (eradication III) leads to approximately 
4.38 million DALYs averted (95% CrI: 2.79m-6.50m) over the same timeframe. Thus, there are 
considerable gains to achieve by more intensely scaling-up MDA.  
Figure 13: Cumulative number of DALYs averted over time per eradication scenario compared to 
the global elimination scenario 
The incremental health impacts by country, expressed as DALYs averted per 100,000 people, are 
depicted for the eradication I scenario compared to the global elimination scenario, eradication II 
compared to eradication I, and eradication III compared to eradication II (Figure 14). The comparison 
between eradication I and the global elimination scenario illustrates that the majority of the gains 
from extending MDA to all endemic countries are concentrated in Central Africa. The heterogeneous 
results within these countries are largely due to demographic patterns that affect the DALY 
estimates, such as age composition, life expectancy, and population growth rates. The gains from 
increasing the rate of MDA scale-up are more evenly spread out among countries (eradication II 
versus I, and III versus II). 
Figure 14: Cumulative number of DALYs averted per 100,000 persons after 50 years per country, 
comparing the different scenarios to each other 
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5.4.2 Cost-effectiveness analysis  
The estimated ICER for the eradication III scenario is approximately 72.9 US dollars (USD)/DALY 
averted (95% CrI: 47.7-110) (Figure 15). In contrast, the eradication I and eradication II scenarios are 
higher, at 219 USD/DALY averted (95% CrI: 143-323) and 121 USD/DALY averted (95% CrI: 79.5-178), 
respectively. Against the global elimination scenario, all eradication scenarios end in the northeast 
quadrant of the incremental cost-effectiveness plane, which implies an increase in DALYs averted at 
increased cost (Figure 16) [120]. Therefore, depending at which threshold the ICER is considered 
good value for money, either the global elimination or eradication III scenario will be most cost-
effective. 
Correspondingly, and as shown by the cost-effectiveness acceptability curve, if the willingness to pay 
threshold per DALY averted is below 71.5 USD, the global elimination strategy should continue to be 
pursued. However, if the willingness to pay threshold surpasses 71.5 USD/DALY averted, then scale-
up of MDA to all at-risk populations in all endemic countries should be pursued as quickly as possible 
(Figure 17).  
Figure 15: Incremental cost-effectiveness ratios associated with each of the scenarios, with global 
elimination as the comparator 
 
Figure 16: Incremental cost-effectiveness plane with incremental financial costs associated with 
MDA programs and incremental disability-adjusted life years averted, comparing the three 
eradication scenarios to the comparator scenario 
 
Figure 17: Cost-effectiveness acceptability curve for the four scenarios 
 
5.4.3 Impact on health system savings and worker productivity losses 
Unsurprisingly, reaching LF eradication sooner was found to correspond to increased health systems 
savings, due to decreased morbidity management, ranging from 140 million USD (95% CrI: 63.8 m-
260m) in the eradication I scenario to 483 million USD (95% CrI: 219m-903m) in eradication III Figure 
18). 
Figure 18: Potential cost savings to LF endemic health systems due to decreased need for 
morbidity management practices 
Potential savings to the health system, however, were dwarfed by possible gains in worker 
productivity, which ranged from approximately 3.4 billion USD (95% CrI: 2.0 bn-5.4 bn) under the 
eradication I scenario to 14.4 billion USD (95% CrI: 8.58bn-22.0 bn) in the eradication III scenario 
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(Figure 19). Importantly, all increased with increasing rates of MDA scale-up, further supporting the 
conclusion from the cost-effectiveness analysis. 
Figure 19: Averted productivity losses due to eradication 
5.5 Discussion 
Lymphatic filariasis could become the first vector-borne disease to be eradicated. While the GPELF 
has made notable progress thus far, in order to achieve eradication, the program needs to be 
extended to several endemic countries. Moreover, if the goal of global elimination as a public health 
problem by 2020, as specified in the London Declaration [121], is to occur, the scale-up of MDA to 
cover all populations at risk needs to be greatly intensified.  
In this analysis, we found that the health impact due to LF eradication will increase with the rate of 
MDA scale-up, since DALYs averted have a longer time period to accrue when transmission is 
interrupted earlier. This highlights the importance of measuring costs and benefits of interventions 
over a long time horizon, as well as the benefits of integrating disease transmission, economic, and 
demographic models. 
Intensifying the rate of MDA scale-up to eradicate LF is also supported on economic grounds. All 
three eradication scenarios ended up in the northeast quadrant of the cost-effectiveness plane 
(Figure 16). Thus, compared to the global elimination scenario, extending MDA to all endemic 
countries is associated with an increase in DALYs averted but at increased cost. Whether this 
investment is worthwhile depends on the willingness to pay of donors. Our analysis suggests that 
above a willingness to pay threshold of 71.5 USD/DALY averted, pursuing eradication at the highest 
level of MDA scale-up is the most likely to provide the greatest net benefits and therefore provide 
the most value for money (Figure 17). To put this in perspective, a willingness to pay of 150 
USD/DALY averted has been suggested for low and middle income countries as an acceptable level 
[122]. While decision makers are not bound by this threshold, our analysis indicates that LF 
eradication would generally be considered cost-effective, assuming the rate of MDA scale-up is 
sufficient. If instantaneous scale-up (eradication III) is shown not to be feasible, the ICER of the 
eradication II scenario (rapid scale-up) remains low at 121 USD/DALY averted. Only at the slowest 
level of scale-up does the ICER fall above this threshold, adding further urgency to intensifying the 
rate of scale-up.  
Other considerations could influence the cost-effectiveness of LF eradication. Depending on the 
perspective taken, the benefits that are expected to arise due to health systems savings and gains in 
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worker productivity could be taken into account, as could potential savings in out-of-pocket costs by 
patients. In both instances, the dominance of the eradication III scenario would further increase. 
There are epidemiological aspects that we did not consider, such as recrudescence of infections in 
areas following elimination due to migration. By ignoring this possibility, we made the implicit 
assumption that international movement among endemic populations was limited. Relaxing this 
assumption would require a meta population model and an investigation of human migration and 
commuting patterns in LF-endemic regions. However, previous studies in which similar mechanisms 
were considered have only added to the growing support for pursuing eradication [115,116].  
Further aspects which could interfere with the ability to maintain sufficiently high MDA coverage 
include insufficient political will, inadequate health infrastructure, logistical issues, and the potential 
of systematic non-compliance. The development of drug resistance, as has been documented in 
animal systems [123], could also present complications. Further, in areas where W. bancrofti is co-
endemic with L. loa, it remains to be seen how effective biannual distribution of ALB by itself or 
together with long lasting insecticidal nets (LLINs) will be. We have assumed that the strategy 
employed in these areas to be equally effective as MDA with IVM and ALB, and equally unlikely to 
lead to resistance. However, if this is not the case, and an alternative strategy requires a larger 
investment or a prolonged campaign, the ICERs of the eradication scenarios will increase. Currently, 
data to improve on these estimates is unavailable but additional modeling work, more focused on 
individual districts based on local data, may be enlightening. Such work could be particularly 
valuable in identifying more effective strategies for dealing with endemic districts where progress 
seems to be lagging.  
Additionally, we assumed that endemic countries implemented MDA programs for a fixed duration 
resulting in a high probability of achieving elimination (i.e., where >97.5% of simulations reached 
elimination) (Chapter 3). A more dynamic decision process, whereby a shorter duration is followed 
by surveys and possible additional rounds of MDA until local elimination is certified may be closer to 
reality, but beyond the scope of this global-level exercise.  
Finally, our strategies assumed that all endemic countries included in the different scenarios are 
committed to elimination, and would not pursue a less ambitious goal, such as disease control. It is 
plausible, however, for some countries to only target populations that live in moderate to high 
transmission zones, but not the greater number of people in low transmission areas where chronic 
disease is much less prevalent. A previous study indeed suggests that cost-effectiveness may 
improve if communities with microfilaria prevalence above 3.55% are first treated through a 
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sequential strategy based first on control and a later shift of program goals towards elimination  
[124]. Ordering the treatment districts by intensity could thus lead to further increases in cost-
effectiveness of our eradication scenarios.  
In conclusion, this study suggests that eradication of LF is likely a cost-effective strategy, and that if 
pursued, scaling up MDA as rapidly as feasible will result in increases in value. 
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Figures 
Figure 13: Cumulative number of DALYs averted over time per eradication scenario compared to 
the global elimination scenario 
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Figure 14: Cumulative number of DALYs averted per 100,000 persons after 50 years per country, 
comparing the different scenarios to each other  
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Figure 15: Incremental cost-effectiveness ratios associated with each of the scenarios, with global 
elimination as the comparator 
 
 
Figure 16: Incremental cost-effectiveness plane with incremental financial costs associated with 
MDA programs and incremental disability-adjusted life years averted, comparing the three 
eradication scenarios to the comparator scenario 
 
These plots highlight the uncertainty around cost-effectiveness ratios.  
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Figure 17: Cost-effectiveness acceptability curve for the four scenarios 
 
Above the cost-effectiveness threshold of 71.5 USD/DALY averted, the probability of the eradication III 
scenario being more cost-effective than the global elimination scenario increases. When eradication III is a 
realistic option, eradication scenarios I and II are never the most cost-effective. 
 
 
Figure 18: Potential cost savings to LF endemic health systems due to decreased need for 
morbidity management practices 
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Figure 19: Averted productivity losses due to eradication 
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6.1 Overall significance of thesis  
Resolution WHA 50.29, adopted by member states in 1997, named lymphatic filariasis (LF) as a 
potentially eradicable disease [9]. Now, as the global health community considers whether to scale-
up the current global elimination program to reach eradication, there is great opportunity to utilize 
the lessons learned from previous and ongoing disease eradication efforts. Additionally, there is 
increased understanding for the need to utilize evidence reflective of the real-world situation to 
make better decisions in order to achieve better health [62]. As such, the work found in this thesis 
aims to provide stakeholders with an evidence base in which to support the decision for proceeding 
to LF eradication.  
This research has direct practical applications at the country and global level by providing important 
insight and comprehensive estimations of many key features to consider prior to committing to LF 
eradication, including: the development of plausible scenarios to reach global elimination and 
eradication, as well as projections of the number of years and amount of treatments required to 
reach the scenario endpoints, the associated financial and economic investment necessary, and the 
benefits resulting from averted LF-related morbidity – assessed in disability-adjusted life years 
(DALYs) averted, possible gains in worker productivity, and potential savings to endemic countries’ 
health systems. In addition to providing the grounds for making decisions about LF eradication, this 
thesis also serves as an example of the type of evidence that could be developed to support 
decisions about proceeding to elimination or eradication for a number of other diseases.  
6.2 Justification of intensifying efforts to eradicate LF 
Lymphatic filariasis is a strong candidate for eradication. LF lacks a significant animal reservoir, is 
inefficiently transmitted, and methods for detecting infection exist and are already in use in many 
endemic areas [33,67]. Progress made by the GPELF also proves that mass drug administration 
(MDA) is an effective strategy to interrupt LF transmission [12,125]. The feasibility of eradicating LF 
is further improved by the fact that all of the drugs used as part of the MDA strategy are currently 
donated by the pharmaceutical companies that manufacture them [10,11].  
Successfully eradicating LF would have many benefits. Unlike elimination, LF eradication would 
result in the permanent end of interventions aimed to interrupt transmission, as well as the 
cessation of necessary surveillance on the disease. Eradicating LF would also remove the threat of 
becoming infected with LF in the future, and the consequent development of LF-related morbidity. 
Successfully eradicating LF would also be a great achievement in public health, and would also 
represent the first vector born disease to be eradicated. The work found in this thesis quantifies 
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many additional benefits of eradicating LF and serves to highlight the reasons why eradication 
should be pursued. As explained in Chapter 5, achieving LF eradication over elimination results in a 
greater health impact, and as such, produces in the greatest savings to the health system and the 
greatest possible increase in worker productivity.  
The work here provides evidence for proceeding to LF eradication as quickly as possible. The 
financial investment necessary to reach eradication is projected to decrease with increased rates of 
MDA scale-up. Under eradication I (average scale-up), 1,289 million USD (95% CrI: 1,227m-1,340m) 
is projected to be required to interrupt LF transmission in all endemic countries. In contrast, 
eradication III (immediate scale-up) is projected to require 1,235 million USD (95% CrI: 1,172m-
1,300m). When taking into account the opportunity costs of the donated drugs and volunteer time, 
immediately providing MDA to all at-risk populations also represents the least investment required. 
The economic costs for the eradication III scenario is estimated at 7.57 billion USD (95% CrI: 7.12bn-
7.94bn), whereas the eradication I scenario is anticipated to have an economic cost of 7.94 billion 
USD (95% CrI: 7.50bn-8.30bn) and eradication II (intensified scale-up) is estimated at 8.00 billion USD 
(95% CrI: 7.55bn-8.35bn). 
 Immediate scale-up also results in the greatest health impact, estimated at 4.38 million DALYs 
averted (95% CrI: 2.79m-6.50m). This estimate contrasts sharply with the health impact of 
eradication I (1.72 million DALYs averted (95% CrI: 1.09m-2.62m)), and eradication II (2.98 million 
DALYs averted (95% CrI: 1.90m-4.45m)). Further, immediate scale-up represents the greatest 
possible savings to the health system over a 50 year time horizon, estimated at 483 million USD (95% 
CrI: 219m-902m). Gains in worker productivity are also anticipated to increase with increased rates 
of MDA scale-up, estimated at over 11 billion USD compared to the eradication I scenario. Given the 
increased benefits and decreased costs associated with the eradication III scenario, it is unsurprising 
that the scenario is also considered the most cost-effective (Table 12).  
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Table 12: Summary of key results with 95% credible intervals 
 Global Elimination Eradication I Eradication II Eradication III 
Number of 
treatments (millions) 
3,409 (3,185-3,538) 4,667 (4,419-4,904) 4,369 (4,133-4,594) 4,159 (3,924-4,382) 
DALYs averted 
(millions)
‡
  
– 1.72 (1.09-2.62) 2.98 (1.90-4.45) 4.38 (2.79-6.50) 
Financial costs  
(millions USD) 
929.2 (883.5-971.5) 1,289 (1,227-1,340) 1,274 (1,209-1,331) 1,235 (1,172-1,300) 
Economic costs  
(billions USD) 
5.21 (4.91-5.45) 7.94 (7.50-8.30) 8.00 (7.55-8.37) 7.57 (7.12-7.94) 
ICER  
(USD/DALY averted)
 ‡
 
– 219.0 (142.7-322.7) 120.7 (79.52-177.7) 72.94 (47.74-109.8) 
Potential savings to 
health system  
(millions USD)
 ‡
 
– 139.9 (63.80-260.3) 335.6 (152.2-626.8) 483.4 (219.1-902.6) 
Potential gains in 
worker productivity 
(billions USD)
 ‡
 
– 3.41 (2.03-5.36) 10.06 (5.98-15.50) 14.43 (8.58-22.02) 
‡Measured against the global elimination scenario as the comparator. 
6.3 Limitations of this work 
This study was undertaken by first developing plausible scenarios to reach global elimination and 
eradication, and then projecting the timeframes and treatments necessary to reach the scenario 
endpoints. The studies on costs, benefits, and cost-effectiveness of eradicating LF were then built 
onto this initial analysis. Thus, assumptions made in developing the scenarios and treatment 
projections impact all additional aspects of this work. While assumptions and limitations from each 
individual analysis are highlighted in the associated chapter, the most significant assumptions used 
to undertake this global-level project are outlined below.   
As with all modeling exercises, the validity and relevance of the outputs are highly dependent upon 
the inputs. We obtained data on both transmission intensity and costs from only a handful of 
countries with endemic LF, all of which were within the same region. In so doing, we made the 
implicit assumption that the data from those countries were representative of the nature of the 
disease in all other endemic countries. Additionally, we relied heavily on the WHO preventive 
chemotherapy (PCT) databank [12] for estimates on current at-risk populations and previous 
progress made against LF. In so doing, we assumed that the number of treatments reportedly 
administered is accurate, both in terms of the number of treatments distributed and the percentage 
of the populations that actually ingested the medications. We also assumed that the level of 
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systematic non-compliance, both historically and prospectively, is not significant enough to have an 
overall effect in any treated population.  
We assumed that the at-risk populations for LF increase with population growth, an assumption that 
has not previously been reflected by WHO estimates. We also considered the prevalence and 
disease distribution data to be correct, though we know that this is not the case in all areas. We did 
not take into consideration the possibility of a technological breakthrough nor the impact of vector 
control. Additionally, we assumed cost data to be representative of the actual expenditure needed 
to undertake the program. And, crucially, we assumed the model estimates reasonably capture the 
factors affecting transmission, costs, and health burden, and that the parameter and model 
uncertainty have been appropriately captured through our parameter ranges, distribution 
assumptions, and sensitivity analyses performed. 
We did not take into account the potential for countries to change priorities or lose interest in 
pursuing LF elimination, and we assumed that the investments necessary to implement the 
programs will continually be provided without interruption. We also assumed that the 
pharmaceutical companies will continue donating the drugs necessary, and that the capacity to 
produce the number of treatments required is available and feasible to deliver without delay. We 
further did not take into consideration the potential for the evolution of drug resistance to become a 
threat to the success of the program. In summary, we assumed that on an operational level, it is 
possible to carry out the program activities as specified by the GPELF, and that those activities will 
lead to the interruption of LF transmission.   
In quantifying the potential health benefits of eradicating LF, we used the official disability weight 
estimates in order to calculate the potential DALYs averted, even though having the same disability 
weight for all manifestation of LF-related disability (including lymphedema, elephantiasis, and 
hydrocele), may be an over-simplification [4]. Further, a recent study by Ton et al. argues for the 
inclusion of LF-related depression in the burden estimates. In assessing the current health burden 
due to LF in this way, the study team found LF to globally account for 5.09 million DALYs, rather than 
the Global Burden of Disease (GBD) estimate of 2.74 million DALYs (1.73m-4.00m) [4,28]. If our study 
had also included the mental health problems associated with LF-related disability, the potential 
benefits of eradicating LF would have been even greater.  
However, assessing the possible benefits of disease eradication in DALYs averted may not be the 
best measure in the first place, as the long term consequences and  broader benefits of eradicating a 
disease are not fully captured. In this study, we chose to evaluate the costs of interrupting 
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transmission and the resulting health benefits over a 50 year time horizon. While the relative cost-
effectiveness between scenarios would likely remain the same regardless of time scale selected, the 
absolute results would have decreased if a shorter time horizon had been chosen, or increased with 
a longer time horizon.  Consequently, there is a need to develop a quantitative measure which takes 
into account the permanent benefits of disease eradication.   
6.4 Policy Implications 
While our study utilized theoretical models, the findings suggest that, pragmatically, all LF endemic 
countries should be equipped with the resources and capacity needed to achieve the scale-up 
specified under eradication III (immediate MDA coverage to all at-risk populations). However, there 
is currently not enough data or experience to assess whether eradication III is feasible in all LF 
endemic countries. Further, there may be specific challenges, national issues, and unforeseen 
circumstances which make the scale-up schedule specified in eradication III difficult in a portion of 
countries. Therefore, special measures should be taken to ensure that, at the very least, all countries 
meet the standards of scale-up outlined under eradication II, in which at least 20% of each country’s 
at-risk population is added to the treatment schedule annually.  In this way, the worst case scenario 
countries with the greatest challenges will reach local elimination by 2032, though the majority of 
countries will still see local elimination before 2028.  
With the exception of the eradication I scenario, the results from the cost-effectiveness analysis are 
well within previously considered acceptable cost-benefit thresholds [122]. The cost-effectiveness of 
the LF eradication program could be further increased, though, by integrating the LF program with 
other disease initiatives. On a global scale, there has already been considerable work towards 
integrating programs. Several public–private partnerships have come together to form the Global 
Network for Neglected Tropical Diseases, an initiative to raise awareness, political will, and funding 
to control and eliminate seven of the most common NTDs [126]. The WHO has also developed 
guidelines for integrated preventive chemotherapy [127], and recently, there has been movement 
towards integrating the African Program for Onchocerciasis Control (APOC) with the Global Program 
to Eliminate LF (GPELF) [128]. Further, many countries have already integrated some of their NTD 
control and elimination activities [109,129,130]. Integrating the LF program with other NTD 
campaigns that carry out similar activities, including: advocacy, trainings, drug distribution, and 
surveillance, is a great first step towards improved efficiency and improved health.   
In addition to integrating similar activities between vertical programs, the LF program could benefit 
further by thinking even more broadly and collaboratively.   
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Table 13 lists diseases that are also impacted by the distribution of the antifilarials used by the 
GPELF. If integration is considered not just in terms of merging similar activities between vertical 
programs, but also in terms of all of the diseases that are impacted by the distribution of the drugs 
used in the LF program, the calculated value and sustainability of the campaign could be further 
increased. As individual NTDs have relatively low global health importance, having a broader 
consideration of all diseases affected would also result in a more visible and better accounted for 
campaign, which may help garner support from stakeholders and the broader public health 
community [23].  
Table 13: Additional diseases affected by the distribution of the GPELF’s antifilarials 
 Global prevalence Region Estimated DALYs 
(millions) 
Global Goal 
Ivermectin 
 
Onchocerciasis  
 
37 million
[127] 
Africa, Americas, Arabian 
Peninsula
[127] 
0.49 (0.36-0.66)
[23] 
Elimination
[127] 
Strongyloidiasis 
 
30-100 million
[131] 
Tropical and sub- Tropical 
areas, some temperate 
regions
[132] 
Unknown
[133] 
None
[134] 
Ascariasis 
 
0.8-1.2 billion
[135]
 Worldwide
[135]
 1.32 (0.71-2.35)
[23] 
Elimination of soil-
transmitted helminth 
(STH)- morbidity in 
children by 2020
[136] 
Trichuriasis 
 
600-800 million
[137] 
Worldwide, mainly 
tropical areas with poor 
sanitation
[138] 
0.64 (0.35-1.06)
[23] 
Elimination of STH- 
morbidity in children 
by 2020
[136]
 
Scabies >130 million
[139] 
Worldwide
[139] 
1.5
[4] 
Control
[140] 
Albendazole 
 
Giardiasis
*
 200 million
[141] 
Worldwide
[142] 
Unknown
 
None 
Trichuriasis 
 
600-800 million
[23] 
Worldwide, mainly 
tropical areas with poor 
sanitation
[138] 
0.64 (0.35-1.06)
[23] 
Elimination of STH- 
morbidity in children 
by 2020
[136]
 
Neurocysticercosis
*
 50 million
[143] 
Latin America, Asia, sub 
Saharan Africa[143] 
0.503 (0.379-0.663)
[4] 
None
[144] 
Hydatid Disease
*
 1 million
[145]
 Worldwide
[145] 
0.143
[4] 
None 
Enterobiasis      
Ascariasis 0.8-1.2 billion
[134]
 Worldwide
[136]
 1.32 (0.71-2.35)
[23] 
Elimination of STH-
related morbidity in 
children by 2020
[136] 
Toxocariasis Unknown. Highly 
variable 
seroprevalence 
rates reported 
[146]
 
Worldwide
[147]
 Unknown
 
None 
Hookworm 600 million
[137] 
Sub Saharan Africa, Latin 
America, Southeast Asia, 
China 
3.23(1.70-5.73)
[23]
 Elimination of STH-
related morbidity in 
children by 2020
[136]
 
*Generally requires more than single dose therapy 
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As observed at the end of previous elimination and eradication campaigns, and also found within our 
LF costing study (Chapter 4), as the number of people to be treated decreases, so too does the 
favorability of measuring the unit treatment costs [66,148]. To sustain momentum during the final 
phase of the program, it has been suggested to change the cost evaluations from cost per person 
treated to cost per case averted [107]. Having a multi-disease initiative would be further beneficial in 
this regard, since the cost per case averted would certainly increase if all diseases impacted by MDA 
for LF were to be considered. Further, since different diseases require different lengths of MDA to 
reach their disease-specific endpoints, milestones and achievements would be reached in a 
staggered manner, which would presumably further propel the overall multi-disease program 
forward by providing evidence of the success of the initiative. Grouping the diseases together could 
also help spread out some of the risk and negative focus that occurs when one individual program 
faces unforeseen obstacles. As such, the risk of donor disillusionment and fatigue would be 
mitigated. Therefore, shifting from a strict vertical thinking approach for LF eradication, to a much 
more inclusive and widespread campaign, could increase cost-effectiveness, while also providing 
numerous additional benefits. 
6.5 Areas of future research and general recommendations  
The evidence laid out in this thesis is sufficient to move forward with increased MDA scale-up to 
reach eradication. While this thesis highlights a number of areas for future research, any such efforts 
should accompany a move towards eradication, not delay it. 
6.5.1 Improved data 
Research on the epidemiological factors and costs associated with eradicating LF, particularly in 
areas with the highest LF burden and where challenges threaten the technical and operational 
feasibility of the current strategy, would aid in planning and policy development. The collection and 
use of expenditure data, both from stand alone and integrated programs, would also be useful at the 
country and global levels. The effect of vector control on LF transmission needs to be further 
investigated, and increased partnerships and strategies to benefit malaria control programs and the 
GPELF should also be utilized. Modeling work is currently underway to assess where the current 
GPELF strategy is likely to achieve local elimination and where alternative approaches are warranted 
[149]. On-the-ground studies to parameterize and validate the models, as well as research on the 
effectiveness of strategies to mitigate some of the potential operational challenges are also needed. 
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6.5.2 Learning for change  
A compilation of best practices and lessons learned from countries that have reached elimination 
would provide valuable guidance to other LF endemic countries that have not yet begun elimination 
efforts, are at the beginning of their programs, or are otherwise struggling to scale-up. 
Acknowledging and learning from other disease elimination and eradication initiatives would also be 
advantageous for the LF program.  
6.5.3 Transparency and governance 
It is hoped that the evidence presented here would be sufficient to convince decision makers of the 
benefits of scaling-up efforts against LF as quickly as possible to reach eradication, though whether 
that is the case remains unclear. On the global level, there needs to be improved transparency in the 
political decision-making process for disease eradication. While an Eradication Investment Case (EIC) 
provides the framework for compiling many components that should be evaluated prior to 
proceeding with disease eradication [61], it would be useful if the type of evidence upon which the 
decision to proceed with eradication were  explicitly specified. 
Further, there needs to be an agency in place to monitor, evaluate, and govern potential and 
ongoing disease eradication initiatives. Such an agency, from here on referred to as a disease 
eradication governing agency (DEGA), would conceivably evaluate the evidence base supporting 
disease eradication initiatives, monitor and assess progress towards eradication milestones, and 
ensure that financial and political commitments are upheld across all partnerships through 
contractual and other legal arrangements. The DEGA would need to be grounded in action rather 
than bureaucracy, as the usefulness of the agency would be heavily dependent upon its ability to 
hold countries, investors, and other stakeholders accountable when milestones are not achieved or 
commitments are not upheld. 
The DEGA should be composed of infectious disease experts alongside implementation advisors, 
contract and finance specialists, and disease eradication thought leaders. By having a core group of 
multidisciplinary experts with experience in disease eradication governing across different disease 
initiatives, problems arising during an eradication initiative may be recognized earlier, and best 
practices for mitigating challenges could be operationalized sooner.  The DEGA could also point out 
activities between ongoing disease eradication initiatives that could be integrated, such as 
surveillance, in order to improve efficiencies and effectiveness on a global scale. By being impartial 
to any disease-specific initiative, the DEGA could also serve to independently evaluate progress 
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towards major milestones in the road to eradication and provide recommendations to improve the 
likelihood of achieving eradication.  
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7 Conclusion 
The justification for this research stems from the necessity for proper planning prior to committing 
to disease eradication. The evidence presented here, while clear limitations in many cases relating to 
the availability and accuracy of data, provides a strong case for increased levels of scale-up to 
eradicate LF. Indeed, across all considerations, including:  time, treatments, level of investments 
necessary, health impact, cost-effectiveness, and broader economic benefits, scaling-up MDA 
coverage to all endemic communities immediately provides the most favorable results. Ultimately, 
though, the success of eradicating LF will depend on the political engagement and enthusiasm at all 
levels.   
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Supplementary material 1: What is Needed to Eradicate Lymphatic Filariasis? A Model-Based 
Assessment on the Impact of Scaling up Mass Drug Administration Programs 
LF model description 
The deterministic transmission model used for the current analysis, EpiFil, has been described in 
detail, validated against multiple data sets for transmission settings with both Anopheles spp. and 
Culex spp. as vectors, and used extensively to predict outcomes of interventions (MDA, vector 
control) for bancroftian lymphatic filariasis [15,47-49]. Specifically, the model versions we used 
largely followed the structure presented by Gambhir & Michael [49], which includes the possibility of 
female worms remaining unmated in humans at low densities, and provides different microfilariae 
uptake functions (facilitation versus limitation) for Anopheles spp. and Culex spp. vectors.  
The model consists of the following partial differential equations used to describe changes in state 
parameters: 
  
  
 
  
  
  
 
 
           
         
  
  
 
  
  
              
  
  
 
  
  
      
The state parameters represent the following: the mean adult worm burden in humans, W; the 
mean microfilariae density in humans, M; the mean level of immunity to infection, I. The initial 
conditions were W(0,t) = M(0,t) = I(0,t) = 0, while W(a,0), M(a,0) and I(a,0) were the equilibrium 
levels in the absence of interventions, obtained numerically by simulating the model for a 
sufficiently long period. The mean L3 density in the mosquito population, L*, is given by: 
   
                  
     
 
and f(M), which combines the moment generating function of the negative binomial distribution of 
infection in humans with the microfilariae uptake curve of individual mosquitoes, as: 
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with f(M)C describing the function used for Culex spp. [15] and f(M)A for Anopheles spp. [49]. The 
worm mating function is given by: 
k 1
( , ) 1 (1 )
2
W
W k
k
    
 
The rate parameters and values used are described in Table S1, while h(a) and π(a) represent the 
age-dependent attractiveness to mosquitoes (we assumed a linear increase from 0 to 1 over the first 
10 years of life and a value of 1 for further years) and an approximation of the human age 
distribution (π(a) = 0·035 e-0·026 a), respectively, as in Norman et al [15]. Typical values are presented 
as examples and for Culex spp. followed that of Norman et al [15], who fitted parameter values to 
reflect transmission of Wuchereria bancrofti by Culex quinquefasciatus in an Indian environment. For 
Anopheles spp. the typical parameter values reflect the average of those presented by Gambhir et al. 
[47] for the Tanzanian sites Tawalani and Masaika. However, as different geographic settings can 
differ dramatically in their parameter estimates [47,48], and because we had a need for varying 
parameter estimates that would result in stable prevalence levels associated with our transmission 
archetypes (ca. 5%, 10%, 15%, and 20% prevalence), we obtained parameter sets that would lead to 
these levels of prevalence while allowing for parameter uncertainty.  
In order to do so, we used a Bayesian framework of importance resampling [47,150]. We first 
defined uninformative ranges for the parameter values based on literature and intuition (Table S1), 
and drew 10,000 sets of random samples from these uniform priors. For each of these randomly 
generated parameter sets, i, the model was simulated for 250 years at which point the stable 
equilibrium prevalence, x, was calculated. The goodness-of-fit of each run to the prevalence level 
associated with the transmission archetype, p, was estimated as a binomial likelihood, 
(1 )
N
L
i x
x N x
p p
 
  
 


 
. We then randomly sampled, with replacement, 500 parameter sets from the 
original 10000 sets proportional to their likelihood, 
LiLi
L
 

 to obtain an approximation of a 
posterior distribution.  
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Supplement Table 1: Parameter descriptions and values used in EpiFil 
Parameter Description Typical value Prior ranges 
  Culex
†
 Anopheles
‡
  
λ human biting rate 10 10.52 6-15 (0.2-0.5 per day) 
V/H vectors per human  576 75.5 50-500 
ψ1 proportion of L3s leaving per 
bite 
0.4 0.45 0.3-0.7 
ψ2s2 proportion of L3s entering 
puncture & establishing  
0.0001 0.004 0.00002-0.004 
g proportion of bites on 
infected humans leading to 
infection 
0.37 0.37 0.25-0.5 
β measure of acquired 
immunity 
[0.031 – 
0.11] 
[0.011 – 
0.047]
#
 
0.001-0.2 
δ decay of immunity 0.004 0 0-0.005 
μ adult worm death rate 0.01 0.01 0.014-0.007 
  adult worm fecundity 2 1.14 0.2-2 
σ mosquito death rate 5 4.68 0.9-6 
γ death rate of mf 0.1 0.095 0.083-0.125 
C MDA coverage 85% 85% - 
μmf microfilaricidal effect 0.95; 0.99 0.95; 0.99 0.9-0.95; 0.95-0.99 
μW macrofilaricidal effect 0.55; 0.35 0.55; 0.35 0.5-0.6; 0.3-0.4 
μ  suppression of worm 
fecundity 
0.95; 0.99 0.95; 0.99 0.9-0.95; 0.95-0.99 
κ constant in L3 uptake 
function  
6 4.39 4-6 
r constant in L3 uptake 
function 
0.047 0.055 0.04-0.06 
k(M)  aggregation parameter 0.0029 + 
0.0236(M) 
0.00203 + 
0.015(M) 
(0.0006-0.002) + (0.01-0.03) M 
†
Parameter values for Culex taken from Norman et al (2000) 
‡
Parameter values for Anopheles taken from Gambhir & Michael (2008) and Gambhir et al (2010) 
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We used these resampled parameter sets to investigate the impact of MDA on LF prevalence over 
time. Examples of prevalences associated with the parameter sets and distributions of a number of 
parameters are given (Figures. S1, S2). 
Supplement Figure 1: Example of microfilariae prevalence levels associated with the set of 
posterior estimates for anopheline transmission (10% prevalence) 
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Supplement Figure 2: Examples of parameter value estimates for different vector genera and MF 
prevalence levels 
 
 
We simulated the effects of filaricidal treatment by including a once-yearly instantaneous killing of a 
proportion of adult worms, μw, and microfilariae, μmf, depending on drug type and level of coverage. 
Additionally, fecundity of worms,  , was reduced for six to nine months following an MDA round by 
a proportion, μα. The impact of MDA programmes was then investigated by repeating these 
treatments for a varying number of years, after which no further intervention took place. For each 
duration (number of MDA rounds), per vector type and drug regimen, we ran 500 simulations 
drawing from the range of posterior parameter estimates, and the lowest number of rounds at 
which in the 95th percentile range of these simulations prevalence was below 1% and decreasing at 
the end of the simulation was taken as a conservative measure of the number of rounds required to 
ensure elimination. Examples of simulations leading to interruption of transmission are given in 
Figure S3, and the predicted number of rounds required are provided in Table 5. 
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Supplement Figure 3: Median values (solid lines) and 95th percentile range (shaded areas) of LF 
prevalence for LF transmission by Anopheles spp. (left) and Culex spp. (right) at four different 
stable levels of pre-intervention LF prevalence 
From top to bottom: 5, 10, 15, 20%), using DEC and albendazole (red) or ivermectin and albendazole (blue) 
combination therapy. 
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Supplementary material 2: How much will it cost to eradicate lymphatic filariasis? An analysis of 
the financial and economic costs of intensified efforts against lymphatic filariasis 
Probabilistic Sensitivity Analysis 
Our micro-costing model was built up using resource quantities and associated unit costs. Following 
guidance from Briggs et. al, we undertook a probabilistic sensitivity analysis (PS) assuming gamma 
distributions, parameterized as gamma(α,β), for all unit cost inputs.. The deterministic value was 
assumed to be the sample mean (µ), with variance s. Which follows: 
   αβ     αβ  
α  
  
  
, β  
  
 
 
[151] 
We assumed 10% variance across all parameters. Supplement Table 2 lists all parameters considered 
along with their deterministic value, calculated standard error, alpha, and beta estimates.  
Supplement Table 2: Parameters used in the Probabilistic Sensitivity Analysis 
Parameters Deterministic 
Value 
Standard 
Error 
Alpha Beta 
Per diem rates     
Case management specialist  $40.00  4.000 100 
                              
0.4000  
Community moderator  $4.68  0.468 100 
                              
0.0468  
CDD - training   $1.17  0.117 100 
                              
0.0117  
CDD - providing data  $0.78  0.078 100 
                              
0.0078  
Clinical officer  $19.50  1.950 100 
                              
0.1950  
Community leaders  $4.68  0.468 100 
                              
0.0468  
Data entry clerk  $78.00  7.800 100 
                              
0.7800  
District representative  $20.00  2.000 100 
                              
0.2000  
District vector control officer  $19.50  1.950 100 
                              
0.1950  
District support staff: district guide  $4.68  0.468 100 
                              
0.0468  
District support staff: local councillor (teachers)  $1.95  0.195 100 
                              
0.0195  
District support staff: local councillor (mobilizer)  $4.29  0.429 100 
                              
0.0429  
Driver  $21.45  2.145 100 
                              
0.2145  
Health promotion and education officer  $41.26  4.000 100                               
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0.4000  
IT consultant  $38.87  4.000 100 
                              
0.4000  
M&E officer  $38.14  4.000 100 
                              
0.4000  
Minister of health  $43.33  5.000 100 
                              
0.5000  
National trainers   $38.50  4.000 100 
                              
0.4000  
NTD Coordinator  $48.79  4.000 100 
                              
0.4000  
Parish supervisors  $ 4.74  0.468 100 
                              
0.0468  
Partners  -     
Procurement officer  $41.36  4.000 100 
                              
0.4000  
Programme managers  $33.25  4.000 100 
                              
0.4000  
Religious leaders  $4.68  0.468 100 
                              
0.0468  
Senior scientist  $42.90  4.290 100 
                              
0.4290  
Social scientists  $40.00  4.000 100 
                              
0.4000  
Sub county supervisors  $4.68  0.468 100 
                              
0.0468  
Support staff, rural  $4.68  0.468 100 
                              
0.0468  
Support staff, urban  $10.00  1.000 100 
                              
0.1000  
Technician  $39.00  3.900 100 
                              
0.3900  
ToTs from District Health Office  $4.68  0.468 100 
                              
0.0468  
ToTs from sub county  $19.50  1.950 100 
                              
0.1950  
Village chief  $4.68  0.468 100 
                              
0.0468  
Materials and supplies     
Accommodation - rural  $11.70  1.170 100 
                              
0.1170  
Accommodation - urban  $100.00  10.000 100 
                              
1.0000  
Advocacy booklets  $1.50  0.150 100 
                              
0.0150  
Air time  $19.50  1.950 100 
                              
0.1950  
Alcohol swab (packet of 100)  $4.68  0.468 100 
                              
0.0468  
Bags for CDDS  $0.39  0.039 100 
                              
0.0039  
Banners  $25.00  2.500 100 
                              
0.2500  
Batteries (size D)  $1.17  0.117 100 
                              
0.0117  
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Billboards  $200.00  20.000 100 
                              
2.0000  
Blood lancets (box of 200 pieces)  $4.68  0.468 100 
                              
0.0468  
Box files  $2.54  0.254 100 
                              
0.0254  
Broadcast spots on radio   $234.00  23.400 100 
                              
2.3400  
Broadcast spots on TV (1 hour)  $390.00  39.000 100 
                              
3.9000  
Capillary tubes (60 ul), 100 pieces  $9.75  0.975 100 
                              
0.0975  
Coartem or (ARCO)  $1.76  0.176 100 
                              
0.0176  
Co-trimazole  Tablets (1000)  $8.27  0.827 100 
                              
0.0827  
Cotton wool (500 gram roll)  $1.95  0.195 100 
                              
0.0195  
Counter book (4 quire)  $2.34  0.234 100 
                              
0.0234  
Dettol soap (100 grams)  $0.98  0.098 100 
                              
0.0098  
Gauze  $3.14  0.314 100 
                              
0.0314  
Gimesa stain  $90.65  9.065 100 
                              
0.9065  
Glass slides (50 pcs)  $2.54  0.254 100 
                              
0.0254  
Gloves (Disposable Rubber)  $4.88  0.488 100 
                              
0.0488  
Hall rental, capital  $150.00  15.000 100 
                              
1.5000  
Hall rental, other  $19.50  1.950 100 
                              
0.1950  
Heparine coated container(200µl)  $0.20  0.020 100 
                              
0.0020  
Ibuprofen Tablets (1000)  $3.90  0.390 100 
                              
0.0390  
Internet and accessories  $1,000.00  100.000 100 
                            
10.0000  
Labels (Packet of 200 labels)  $1.95  0.195 100 
                              
0.0195  
Laundry soap - bar  $1.17  0.117 100 
                              
0.0117  
Laundry soap -Detergent powder (1 kg)  $3.12  0.312 100 
                              
0.0312  
Magnesium trisilicate (1000)  $2.93  0.293 100 
                              
0.0293  
Match box (10 pieces)  $0.39  0.039 100 
                              
0.0039  
Meals, capital  $7.80  0.780 100 
                              
0.0780  
Megaphone  $45.00  4.500 100 
                              
0.4500  
Mobile phones  $80.00  8.000 100 
                              
0.8000  
Neomycin ointment (12)  $7.02  0.702 100 
                              
0.0702  
Paracetamol Tablets (1000)  $3.90  0.390 100 
                              
0.0390  
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Paraffin  $0.94  0.094 100 
                              
0.0094  
Pens (packets of 50)    $0.20  0.020 100 
                              
0.0020  
Pencils (HB) dozens  $0.02  0.002 100 
                              
0.0002  
Permanent marker  $2.60  0.260 100 
                              
0.0260  
Photocopying paper  $6.63  0.663 100 
                              
0.0663  
Pipette tips  $0.39  0.039 100 
                              
0.0039  
Pamphlets for districts  $0.39  0.039 100 
                              
0.0039  
Posters  $1.17  0.117 100 
                              
0.0117  
Refreshments, capital  $5.00  0.500 100 
                              
0.0500  
Refreshments, rural  $1.37  0.137 100 
                              
0.0137  
Reproduction of advocacy materials  $0.10  0.010 100 
                              
0.0010  
Safety boxes (Sharps container)  $0.39  0.039 100 
                              
0.0039  
Sentinel site forms  $0.03  0.003 100 
                              
0.0003  
Stationary  $1.17  0.117 100 
                              
0.0117  
Survey forms  $0.03  0.003 100 
                              
0.0003  
Sweets   $5.85  0.585 100 
                              
0.0585  
Test kits - Binax Now(25 test kits)  $5.48  0.548 100 
                              
0.0548  
Trash bags (50 pieces)  $1.95  0.195 100 
                              
0.0195  
Trash containers (50 pieces)  $1.95  0.195 100 
                              
0.0195  
Toilet paper (20 roll carton)  $4.29  0.429 100 
                              
0.0429  
T-shirts $3.90 0.390 100 
                              
0.0390  
Activities     
Data cleaning/ Entry Clerk/Analysis  $975.00  97.500 100 
                              
9.7500  
Institution review clearance fees  $210.60  21.060 100 
                              
2.1060  
Report writing (lump sum)  $195.00  19.500 100 
                              
1.9500  
Slide reading  $0.39  0.039 100 
                              
0.0039  
Data analysis  $195.00  19.500 100 
                              
1.9500  
Demographics     
# of people per district 
                         
279,089  27909 100 
                       
2,790.8900  
# people per subdistrict 
                           
18,006  1801 100 
                          
180.0600  
# parishes per district 
                                  
64  6 100 
                              
0.6400  
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# people per village 
                                
730  73 100 
                              
7.3000  
# schools per district 
                                
209  21 100 
                              
2.0894  
Personnel Salaries – WHO CHOICE     
 Programme Director     
AFRO D  $35,948.45  3594.845 100 
                          
359.4845  
AFRO E  $35,592.05  2371.055 100 
                          
237.1055  
AMR B  $46,422.24  4642.224 100 
                          
464.2224  
AMR D  $35,882.89  2390.366 100 
                          
239.0365  
EMR D  $8,828.88  882.888 100 
                            
88.2888  
SEAR B  $21,010.75  2101.075 100 
                          
210.1075  
SEAR D  $29,322.32  1953.391 100 
                          
195.3391  
WPR A  $119,654.14      11965.414 100 
                       
1,196.5414  
WPR B  $41,810.53  4181.053 100 
                          
418.1053  
     
Program Manager     
AFRO D  $23,947.75  2394.775 100 
                          
239.4775  
AFRO E  $23,710.55  1464.328 100 
                          
146.4328  
AMR B  $30,925.51  3092.551 100 
                          
309.2551  
AMR D  $23,903.65  1476.367 100 
                          
147.6367  
EMR D  $5,881.15  588.115 100 
                            
58.8115  
SEAR B  $13,997.24  1399.724 100 
                          
139.9724  
SEAR D  $19,533.91  1206.387 100 
                          
120.6387  
WPR A  $79,710.23  7971.023 100 
                          
797.1023  
WPR B  $27,853.82  2785.382 100 
                          
278.5382  
  Administrative Assistant     
AFRO D  $14,791.08  1479.108 100 
                          
147.9108  
AFRO E  $14,643.28  1109.242 100 
                          
110.9242  
AMR B  $19,100.04  1910.004 100 
                          
191.0004  
AMR D  $14,763.67  1118.301 100 
                          
111.8301  
EMR D  $3,631.92  363.192 100 
                            
36.3192  
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SEAR B  $8,645.32  864.532 100 
                            
86.4532  
SEAR D  $12,063.87  913.760 100 
                            
91.3760  
WPR A  $49,230.51  4923.051 100 
                          
492.3051  
WPR B  $17,202.43  1720.243 100 
                          
172.0243  
Finance Officer     
AFRO D  $11,203.27  1120.327 100 
                          
112.0327  
AFRO E  $11,092.42  1109.242 100 
                          
110.9242  
AMR B  $14,466.87  1446.687 100 
                          
144.6687  
AMR D  $11,183.01  1118.301 100 
                          
111.8301  
EMR D  $2,751.05  275.105 100 
                            
27.5105  
SEAR B  $6,547.46  654.746 100 
                            
65.4746  
SEAR D  $9,137.60  913.760 100 
                            
91.3760  
WPR A  $37,289.41  3728.941 100 
                          
372.8941  
WPR B  $13,030.55  1303.055 100 
                          
130.3055  
Data Entry Clerk     
AFRO D $11,203.27  1120.327 100 
                          
112.0327  
AFRO E 
                   
$11,092.42  1464.328 100 
                          
146.4328  
AMR B 
                   
$14,466.87  1446.687 100 
                          
144.6687  
AMR D 
                   
$11,183.01  1476.367 100 
                          
147.6367  
EMR D 
                     
$2,751.05  275.105 100 
                            
27.5105  
SEAR B $6,547.46  654.746 100 
                            
65.4746  
SEAR D $9,137.60  1206.387 100 
                          
120.6387  
WPR A  $37,289.41  3728.941 100 
                          
372.8941  
WPR B  $13,030.55  1303.055 100 
                          
130.3055  
Supplies Manager     
AFRO D  $14,791.08  1479.108 100 
                          
147.9108  
AFRO E  $14,643.28  3559.205 100 
                          
355.9205  
AMR B  $19,100.04  1910.004 100 
                          
191.0004  
AMR D  $14,763.67  3588.289 100 
                          
358.8289  
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EMR D  $3,631.92  363.192 100 
                            
36.3192  
SEAR B  $8,645.32  864.532 100 
                            
86.4532  
SEAR D  $12,063.87  2932.232 100 
                          
293.2232  
WPR A  $49,230.51  4923.051 100 
                          
492.3051  
WPR B  $17,202.43  1720.243 100 
                          
172.0243  
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Supplementary material 3: Modelling the health impact and cost-effectiveness of lymphatic 
filariasis eradication under varying levels of mass drug administration scale-up and geographic 
coverage 
Scenarios 
The elimination and eradication scenarios are based on an analysis of the currently ongoing 
elimination programme. Their composition are described in detail in Chapter 3. Briefly, the scenarios 
were based on the mass drug administration of filaricidal drugs: albendazole (ALB) either in 
combination with diethylcarbamazine citrate (DEC) or, in areas where coendemicity of Onchocerca 
volvulus is a concern, with ivermectin (IVM).  
To account for heterogeneity in transmission intensity within countries, we assigned proportions of 
each at-risk population to transmission archetypes of approximately 0% (i.e., the proportion of 
implementation units (IUs) that were false positive), 5%, 10%, 15% and 20% microfilaremia 
prevalence. The data reflected the situation in African countries, i.e., the proportion of endemic 
implementation units that fell within >0-5% prevalence, 5-10%, 10-15%, or >15%. The archetypes 
used in the analysis reflect an upper boundary to the underlying data, save for the highest level, 
where a 20% prevalence was taken as a representation of very high transmission levels. The average 
proportion of IUs that fell within these categories was used for all countries, and uncertainty in this 
estimate was included by treating these averages as a probability in a multinomial distribution 
(Chapter 3). 
We used the number of treatment estimates required for each year, in each LF-endemic country and 
each scenario from Chapter 3. These estimates were derived upon the number of annual treatment 
rounds of MDA necessary, taking into consideration the underlying microfilaria prevalence quartiles 
in each country, whether transmission is due to Anopheles spp. or Culex spp., the drug regimen used, 
and the number of effective MDA rounds that had already occurred prior to 2013. These estimates 
are conservative in the sense that they allowed the credible interval of our simulations to achieve 
elimination. We thus assumed that public health officials implemented MDA programmes of these 
durations in order to assure a high probability of achieving elimination.  
We used these estimated durations to predict the number of treatments required per year for each 
of the elimination and eradication scenarios, as well as to develop estimates of the financial and 
economic costs associated with implementing the scenarios (Chapter 4). 
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Model 
We used two versions of the deterministic model, EpiFil , to simulate adult filarial worm, microfilaria 
and infective stage larvae (L3) transmission and dynamics when the mosquito vectors were either 
Anopheles or Culex spp. The model versions we used largely followed the structure presented by 
Gambhir & Michael [49], which includes the possibility of female worms remaining unmated in 
humans at low densities, and provides different microfilariae uptake functions (facilitation and 
limitation) for Anopheles spp. and Culex spp. vectors. We assumed that transmission by other 
mosquito genera (e.g., Aedes, Mansonia) is approximated well enough by these model versions. 
The transmission model was thus the same as used and described in our related analysis (Chapter 3) 
and is described in detail in the supplementary material. The model consists of the following partial 
differential equations used to describe changes in state parameters: 
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The state parameters represent the mean adult worm burden in humans, W; the mean microfilariae 
density in humans, M; and the mean level of immunity to infection, I. The initial conditions were 
W(0,t) = M(0,t) = I(0,t) = 0, while W(a,0), M(a,0) and I(a,0) were the equilibrium levels in the absence 
of interventions, obtained numerically by simulating the model for a sufficiently long period. L*, the 
mean L3 density in the mosquito population, is given by: 
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The functions h(a) and π(a) represent the age-dependent availability to mosquitoes (represented as 
a linear increase from 0 to 1 over the first 10 years of life and a value of 1 for further years) and an 
approximation of the human age distribution (π(a) = 0·035 e-0·026 a), respectively, as in Norman et al. 
[15]. The population-averaged uptake of infective stage filarial larvae by mosquitoes, f(M), is defined 
as: 
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(6) 
with f(M)C describing the function used for Culex spp. [15] and f(M)A for Anopheles spp. [49]. The 
worm mating function [49,152] is given by: 
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(7) 
To assess the resulting health impact of the different scenarios, the progression of disease, adapted 
from the ordinary differential equations of Chan et al. [153], was added to the model of lymphatic 
filariasis transmission. These equations suggest that progression to hydrocele and lymphedema 
result directly from damage to the lymphatic system that accrues due to harbouring adult worms 
over time. Different grades of lymphedema or hydrocele, or other aspects of disability related to LF, 
are not accounted for:  
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(10) 
where D represents the mean proportion of humans with lymphatic damage; the mean proportion 
of humans with lymphedema is given by L; and the mean proportion of males in areas where W. 
bancrofti is the causative agent with hydrocele by H. The rate parameters and range of prior values 
used are described in Error! Reference source not found. 1.  
Parameter estimation 
We used the same posterior parameter estimates for the parameters of the transmission model (i.e, 
those appearing in equations 1-7) that resulted in stable prevalence levels associated with the 
transmission archetypes (ca. 5%, 10%, 15%, and 20% prevalence) as used in Chapter 3, as well as the 
expected durations of MDA programmes in the different transmission settings. The effects of 
filaricidal treatment were included through a once-yearly instantaneous killing of a proportion of 
adult worms, μw, and microfilariae, μmf, within the proportion of humans (85%) covered by the 
programs. Additionally, the fecundity of adult worms,  , was reduced to zero for six to nine months 
following a round of MDA within treated humans [76]. The exact values of these killing parameters 
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were randomly sampled from their ranges to allow for a degree of uncertainty in the efficacy of MDA 
programmes. 
The parameters related to the disease model (those in equations 8-10) were estimated for each of 
the four levels of prevalence associated with our archetypes using the same importance-resampling 
method as previously (Chapter 3), and similar to that which has been used to fit EpiFil to 
transmission patterns in specific geographic settings [47,48]. For the purpose of obtaining disease 
parameter estimates, we fixed the transmission related parameters at the medians of their 
previously estimated values (Chapter 3), while for the disease-related parameters we drew 10,000 
random samples from their uninformative prior ranges. A relation between the prevalence of 
chronic disease states due to LF (hydrocele and lymphedema) and microfilaria prevalence in given 
localities has been investigated and these data are presented by Michael et al. [124]. These data are 
replotted (Supplementary Figure 4a), and the median and interquartile ranges of the data points 
binned per the prevalence levels associated with our transmission archetypes are depicted in 
Supplement Figure 4. 
We ran 10,000 simulations and calculated the goodness of fit of each simulation to the data on 
chronic disease prevalence. Because we required estimates of the prevalence of hydrocele and 
lymphedema, rather than a combined prevalence of chronic disease, the total prevalence was 
decomposed to male and female prevalence following the global estimate of Michael et al. [79], so 
that Prcd,male = Prcd,total*1·75 and Prcd,female = Prcd,total*0·25, where Prcd,male is equal to  Prl+h and Prcd,female 
is equal to  Prl. We therefore make the simplifying assumptions that males and females acquire 
lymphedema at equivalent rates, and that co-occurrence of lymphedema and hydrocele in males is 
rare. The goodness of fit to a point prevalence level was assessed through a binomial likelihood: 
xsp (1 )s
,
N N xsL psi xss m f
    
  , where N is the human population size (assumed to be 1000), ps the 
target prevalence levels of disease associated with the transmission archetype, and xs is the 
simulated number of afflicted humans for the simulation run with parameter set, i. Male and female 
populations are indicated by s. We then randomly sampled, with replacement, 500 parameter sets 
from the original 10000 sets proportional to their likelihood, 
LiLi
L
 
  to obtain an approximation 
of their posterior distribution [47]. The prevalence of chronic LF-induced disease outcomes from sets 
of 500 simulations using the resampled parameter sets are depicted (Supplement Figure 5). 
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Supplement Figure 4: The relation between prevalence of microfilaremia and chronic disease used 
to fit disease model parameters 
 
Data points and leftmost panel reproduced from Michael et al (2008) [124]. Middle: The median and 
interquartile ranges of the data points binned per prevalence levels associated with transmission archetypes. 
Right: Probability densities of chronic disease outcomes from sets of 500 simulations using resampled 
parameter sets. 
 
Assessing the disability-adjusted life years averted by the eradication scenarios 
Based on the results of the transmission and disease model, and accounting for the different 
transmission archetypes and the number of MDA rounds that countries had already completed, the 
mean prevalence of lymphedema and hydrocele for each age class over a period of 50 years was 
computed and recorded as matrices Pl(t,a) and Ph(t,a). In areas where Brugian filariasis 
predominates, we assumed that males are not affected by hydrocele and that lymphedema 
progressed as in Bancroftian filariasis. This was implemented for 20% of the Philippines and 60% of 
Indonesia, based on the ratio of prevalences between types [79], rounded up or down. 
To translate prevalence to incidence per age class, we used country-specific demographic 
parameters (proportion alive at age x; life expectancy at age x; sex ratio at birth; population growth 
rate) [79]. This resulted in matrices Af(t,a) and Am(t,a) which gave the population sizes per five year 
age class over time, by sex. For each country we calculated the incidence per age per year for both 
males and females:   
      ,   ,   ,, , , , , , , , ,I t a P t a A t af i j k l i j k f i j k é  (1) 
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          , , , , , , , , , , , , , , ,,   ,   ,   ,   ,m i j k l i j k m i j k h i j k m i j kI t a P t a A t a P t a A t a é é  (2) 
 
where the matrices are multiplied using the Hadamard product (i.e., element-wise), subscript i 
indicates the deciles within a country which differ only in their history of MDA, j indicates the four 
transmission intensity levels, and k each of the 500 iterations of the model. We then summed the 
cases over the deciles, If,j,k(t,a) and Im,j,k(t,a), and obtained the number of new cases per 5-y-period 
and 5-y-age-group, as: 
      , , ,1,   1, 1  ,j k j k j kN t l a I t l a I t l a         (3) 
 
where l = [1, 2,...,10] indicates the 5-y-periods considered. For each age-group and each period, we 
calculated the YLDs by multiplying the number of new cases by the remaining expectation of life of 
that age group, el, and the disability weight (DW) of LF-related chronic disease, for males and 
females (s):  
    
1
,   ,  
, ,s , ,
D t a N t a e dw tj k j k s l dr
  (4) 
 
where the future discounting rate, dr, was set to 1·03. 
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Supplement Figure 5: Mean and standard deviation of 500 simulations of prevalence of 
lymphedema and hydrocele for the anopheline model version  
 
Mean and standard deviation of 500 simulations of prevalence of lymphedema and hydrocele for the 
anopheline model version Assuming 20% microfilaremia over time by age, using once-yearly 
diethylcarbamazine and albendazole administration for 7 years to interrupt transmission, starting at year 0 
 
Assessing costs of implementing the global elimination and eradication scenarios  
The costs of the scenarios modelled were estimated from the perspective of each LF-endemic 
country’s health system. USAID’s NTD Master Plan Costing Tool in the African Region from eight 
AFRO countries were reviewed to assess essential activities and resources needed to undertake the 
GPELF strategy at a country level. Essential activities, resources, and their associated costs were then 
confirmed by the LF elimination team in Uganda.  All costs are reported in 2012 U.S. dollars and 
discounted at 3%.  
Using Ugandan costs as a reference, the prospective costs for non-tradable goods and services in all 
other LF-endemic countries were imputed by adjusting with country-specific purchasing power 
parity (PPP) conversion factors [93].  All laboratory supplies and capital items were valued at their 
recommended retails prices. Salaries, as well as prices that were unable to be determined 
elsewhere, were taken from the WHO-CHOICE databank [16]. Additional details on the costing 
methodology can be found in Chapter 4. 
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Lymphatic filariasis related morbidity 
Lymphedema  
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Elephantiasis 
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Hydrocele 
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Preventative Interventions for LF 
Determination of ivermectin dosage 
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School-based Mass Drug Administration 
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Community-based Mass Drug Administration 
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